Name and email
M. Auger; M.D.,C.M. (McG.), F.R.C.P.(C)
Email: manon.auger [at] mcgill.ca (Dr. Manon Auger)
After obtaining her MD degree at McGill University, Dr. Auger completed her residency training in Anatomical Pathology at the University of Toronto, followed by a Cytopathology Fellowship at the University of Texas M.D. Anderson Cancer Center in Houston.
Dr. Auger is Professor in the Department of Pathology at McGill University and has been Director of the Cytopathology Laboratory at the Royal Victoria Hospital/McGill University Health Center since 1994.
Dr. Auger has given numerous cytopathology-related lectures and workshops in Canada as well as internationally. She was the Director of the McGill Cytopathology Review Course which was been held annually in Montreal for 16 years (2002-2019). She is the Director of the Area of Focused Competence in Cytopathology program at McGill University which is a program accredited by the Royal College of Physicians and Surgeons of Canada providing advanced (post-residency) cytopathology training..
Her interests include all aspects of cytopathology and she is passionate about teaching.
Special Interests and Research Areas
- Fine needle aspiration cytology, in particular from the thyroid gland
- Quality Improvement in cytopathology
- Urinary cytopathology
Evidence-based diagnostic accuracy measurement in urine cytology using likelihood ratios. Myles N, Auger M, Kanber Y, Caglar D, Kassouf W, Brimo F J Am Soc Cytopathol 2021;10:71-78.
Immunocytochemistry for diagnostic cytopathology—A practical guide. Kanber Y, Pusztaszeri M, Auger M. Cytopathology 2021; 32:562-587.
Breast implant-associated anaplastic large cell lymphoma and effusions: A review with emphasis on the rôle of cytopathology. Julien LA, Michel RP, Auger M. Cancer (Cancer Cytopathol) 2020; 128:440-451 (doi: 10.1002/cncy.22233).
A practical guide for ancillary studies in pulmonary cytologic specimens. Auger M, Brimo F, Kanber Y, Fiset PO, Camilleri-Broet S Cancer Cytopathology 2018;126:599-614 (DOI: 10.1002/cncy.22028)
M.N. Burnier Jr.; M.D., Ph.D. (Brazil)
Email: miguel.burnier [at] mcgill.ca (Dr. Miguel Burnier)
(joint appointment with Opthomology)
Dr. Miguel Burnier was the Chairman of the Department of Ophthalmology, McGill University, from 1993 to 2008. He is a Full Professor of Ophthalmology, Pathology, Medicine and Oncology at McGill and he was also the Thomas O. Hecht Family Chair in Ophthalmology (1996-2012). This is the first and the only endowment Chair of the Department of Ophthalmology. It was awarded to Dr. Burnier upon his arrival as Professor and Chair of the Department of Ophthalmology. Dr. Burnier is currently the General Director of Clinical Research & Training of the McGill University Health Centre Research Institute.
An extremely active researcher with a particular interest in uveal melanoma, Dr. Burnier is the Director of the Henry C. Witelson Ocular Pathology Laboratory. The Laboratory is a unique facility in Canada and has become the largest research and training center in Ocular Pathology in North America. It plays a crucial role as a consultancy service to Pathologists, Ophthalmologists and Oncologists and a teaching facility to medical students, residents and fellows from around the world. Over 125 fellows from different countries have passed through Dr. Burnier’s lab.
The laboratory offers the only Ocular Pathology graduate program in North America. Since 1999, over 20 graduate students of the Laboratory completed their thesis at the Pathology Graduate Program, McGill University. Also during this time, 30 international graduate students from Federal University of Sao Paulo, Brazil; University of Valladolid and University of Barcelona, Spain and University of Coimbra, Portugal completed their thesis. CEGEP students from Marianopolis College and Dawson College spend a week in the Laboratory as part of a special program to introduce them to research.
Dr. Burnier is the author and co-author of over 500 publications including, 330 peer reviewed papers, 251 peer reviewed abstracts, over 60 publications in various scientific journals, three books and 18 book chapters. Dr. Burnier has served as Guest Speaker and Visiting Professor at many conferences and symposia across Canada, the United States, Europe and South America. He is an active member of over 20 societies and serves as an Editorial Board Member for Investigative Ophthalmology & Visual Sciences (IOVS). He is also a reviewer for several ophthalmology publications such as, The American Journal of Ophthalmology; Ophthalmology; Cancer and Melanoma Research, and The British Journal of Ophthalmology among others. Dr. Burnier was the Editor- in- Chief of The Canadian Journal of Ophthalmology from 2002-2005. Dr. Burnier also holds international appointments such as Professor of Post Graduate Studies and Thesis Supervisor for the Department of Ophthalmology, Federal University of Sao Paulo, Brazil; Professor of Ophthalmology and Pathology, University of Valladolid, Spain; and Professor and Consultant Pathologist for the Armed Forces Institute of Pathology (AFIP) American Registry of Pathology, Washington.
Dr. Burnier has won many awards including The University of Sao Paulo’s Gold Medal in Ophthalmology, The European Ophthalmology Award of Excellence, the American Academy of Ophthalmology Award of Excellence and The Pan American Association of Ophthalmology Life Achievement Award. In research, Dr Burnier received the WHO award for Melanoma research. In 2009, Dr. Burnier received the FARVO medal from the ARVO for his research contributions to the field of Ocular Pathology and Oncology. Recently, in 2012 Dr. Burnier received The Brazilian Academy of Science Award & Membership in Rio de Janeiro, Brazil.
Among his teaching awards, Dr. Burnier has received the 2006 Gradle Teaching Award given by the American Academy of Ophthalmology/Pan American Association of Ophthalmology. At McGill, Dr. Burnier was named to the Faculty Honour List for Educational Excellence in 2007. In Canada, Dr. Burnier received the Frederick Feldman Teaching Award from the University of Toronto. Dr. Burnier is the recipient of the Rio Branco Medal, which corresponds to the Order of Brazil. He is also the Chair #45 of the “Academia Ophthalmologica Internationalis.”
In celebration of the 10th Year Anniversary of the Henry C. Witelson Ocular Pathology Laboratory, the Burnier International Ocular Pathology Society (BIOPSY) was founded. The inaugural meeting of the society was in Montreal, May 6-8, 2010. The second meeting was held in Valladolid, Spain in 2012 and the third meeting was held in Balneario Camboriu, Brazil in April 2014. BIOPSY currently has 120 members and is known for its continuous growth worldwide.
A cystic epithelial downgrowth mimics an intraocular tumour following penetrating eye trauma.
Jagan LG, Discepola G, Al-Sharif E, Bravo-Filho V, Burnier MN Jr.
Can J Ophthalmol. 2014 Aug;49(4):e94-6.
Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
Faingold D, Filho VB, Fernandes B, Jagan L, de Barros AM Jr, Orellana ME, Antecka E, Burnier MN Jr.
Pathol Res Pract. 2014 Nov;210(11):739-45.
Balloon cell nevus of the iris.
Morcos MW, Odashiro A, Bazin R, Pereira PR, O'Meara A, Burnier MN Jr.
Pathol Res Pract. 2014 Dec;210(12):1160-3
Expression of the metastasis suppressor BRMS1 in uveal melanoma.
Ventura BV, Quezada C, Maloney SC, Fernandes BF, Antecka E, Martins C, Bakalian S, di Cesare S, Burnier MN Jr.
Ecancermedicalscience. 2014 Mar 11;8:410
Case report: an atypical peripapillary uveal melanoma.
Lim LA, Miyamoto C, Blanco P, Bakalian S, Burnier MN Jr.
BMC Ophthalmol. 2014 Feb 3;14:13.
Rapid growth of an orbital hemangiopericytoma with atypical histopathological findings.
Pacheco LF, Fernandes BF, Miyamoto C, Maloney SC, Arthurs B, Burnier MN Jr.
Clin Ophthalmol. 2014;8:31-3.
Hypoxia-inducible factor-1α and its role in the proliferation of retinoblastoma cells.
Fernandes BF, Coates J, Odashiro AN, Quezada C, Huynh A, Odashiro PR, Odashiro M, Burnier MN Jr.
Pathol Oncol Res. 2014 Jul;20(3):557-63.
Local chemotherapeutic agents for the treatment of ocular malignancies.
Fernandes BF, Nikolitch K, Coates J, Novais G, Odashiro A, Odashiro PP, Belfort RN, Burnier MN Jr.
Surv Ophthalmol. 2014 Jan-Feb;59(1):97-114
|934-1934 ex. 38773
A. Ferenczy; B.A., B.Sc., M.D. (Montr.)
Email: alex.ferenczy [at] mcgill.ca (Dr. Alex Ferenczy)
R. Fraser; B.Sc., M.D., C.M. (McG.), M.Sc.(Glas.) F.R.C.P.(C)
Email: richard.fraser [at] mcgill.ca (Dr. Richard Fraser)
Z-H. Gao, M.D., Ph.D., F.R.C.P.(C) (adjunct)
Email: zuhua.gao [at] ubc.ca (Dr. Zu-hua Gao)
Dr. Zu-hua Gao obtained his Medical degree from Qingdao Medical College, Master degree from Harbin Medical University, and PhD degree from Peking Union Medical College. Dr. Gao received his post-doctoral fellowship training at the Johns Hopkins Hospital, pathology residency training at Dalhousie University, and subspecialty pathology fellowship at the University of Chicago. As a surgical pathologist, Dr. Gao’s clinical expertise is gastrointestinal and liver pathology. As an educator, Dr. Gao teaches undergraduate medical students pathology courses, supervises graduate students, residents, and fellows. Dr. Gao has written three textbooks: the Clinical Skills Review for medical students (3editions), the Pathology Review and Practice Guide book for pathology residents (2 editions, translated into 4 languages) and Gross Morphology of Common Diseases. As a research scientist, Dr. Gao published 168 peer reviewed articles, over 70 abstracts and meeting presentations, and 25 invited speeches at national and international venues. Dr. Gao received many awards including the Junior Scientist Award at CAP-ACP, the Dalhousie Medical Foundation award, the McGill University Health Center Foundation award, etc. As an administrator, Dr. Gao had been the Division Head of Anatomical Pathology and Cytopathology at the University of Calgary and Calgary Laboratory Services between 2007-2011. Since 2012, Dr. Gao has been the Chair and Chief of the Department of Pathology at McGill University. Since 2019, Dr. Gao has been the President of Canadian Chairs of Pathology and Laboratory Medicine. In 2017, Dr. Gao became a Fellow of the Royal Society of Medicine (London UK). In 2019, Dr. Gao became a Fellow of the Canadian Academy of Health Sciences.
Dr. Gao's main areas of research focus on neoplastic and non-neoplastic liver diseases, and colon cancer.
Sinusoidal endotheliitis as a histological parameter for diagnosing acute liver allograft rejection
Shi Y, Dong K, Zhang YG, Michel RP, Marcus V, Wang YY, Chen Y, Gao ZH.
World J Gastroenterol. 2017 Feb 7;23(5):792-799. doi: 10.3748/wjg.v23.i5.792.
Role of CCN5 (WNT1 inducible signaling pathway protein 2) in pancreatic islets
Liu JL, Kaddour N, Chowdhury S, Li Q, Gao ZH
J Diabetes. 2016 Nov 12. doi: 10.1111/1753-0407.12507
Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma
Li Q, Wang H, Zogopoulos G, Shao Q, Dong K, Lv F, Nwilati K, Gui XY, Cuggia A, Liu JL, Gao ZH
Oncotarget. 2016 Nov 22;7(47):77838-77853. doi: 10.18632/oncotarget.12834.
[Corrigendum] Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs
Gao B, Shao Q, Choudhry H, Marcus V, Dong K, Ragoussis J, Gao ZH
Int J Oncol. 2017 Jan;50(1):339. doi: 10.3892/ijo.2016.3722. Epub 2016 Oct 6.
Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs
Gao B, Shao Q, Choudhry H, Marcus V, Dong K, Ragoussis J, Gao ZH.
Int J Oncol. 2016 Sep;49(3):1108-18. doi: 10.3892/ijo.2016.3591. Epub 2016 Jun 30.
Clonal Characteristics of Circulating B Lymphocyte Repertoire in Primary Biliary Cholangitis
Tan YG, Wang YQ, Zhang M, Han YX, Huang CY, Zhang HP, Li ZM, Wu XL, Wang XF, Dong Y, Zhu HM, Zhu SD, Li HM, Li N, Yan HP, Gao ZH
J Immunol. 2016 Sep 1;197(5):1609-20. doi: 10.4049/jimmunol.1600096. Epub 2016 Jul 18.
Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis.
Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Anders RA, Gao ZH.
Histopathology. 2010 May;56(6):683-93.
Distinction of hepatocellular adenoma from hepatocellular carcinoma with and withoutcirrhosis using E-cadherin and matrix metalloproteinase immunohistochemistry.
Tretiakova MS, Hart J, Shabani-Rad MT, Zhang J, Gao ZH.
Mod Pathol. 2009 Aug;22(8):1113-20.
Intravascular lymphocytosis in acute appendicitis: potential mimicry of chronic lymphocytic leukaemia.
Lee S, Ogilvie RT, Dupre M, Gao ZH.
Histopathology. 2009 Dec;55(6):660-4.
Seeking beyond rejection: an update on the differential diagnosis and a practical approachto liver allograft biopsy interpretation.
Adv Anat Pathol. 2009 Mar;16(2):97-117.
Primary hepatic malignant fibrous histiocytoma: clinicopathologic characteristics andprognostic value of ezrin expression.
Li YR, Akbari E, Tretiakova MS, Hart J, Akbari M, Urbanski SJ, Gao ZH.
Am J Surg Pathol. 2008 Aug;32(8):1144-58.
The impact of pathologist experience on liver transplant biopsy interpretation.
Coffin CS, Burak KW, Hart J, Gao ZH.
Mod Pathol. 2006 Jun;19(6):832-8.
Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors ofmetalloproteinases with the progression and metastasis of hepatocellular carcinoma.
Gao ZH, Tretiakova MS, Liu WH, Gong C, Farris PD, Hart J.
Mod Pathol. 2006 Apr;19(4):533-40.
Repopulation of liver endothelium by bone-marrow-derived cells.
Gao Z, McAlister VC, Williams GM.
Lancet. 2001 Mar 24;357(9260):932-3.
Sirolimus-tacrolimus combination immunosuppression.
McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS.
Lancet. 2000 Jan 29;355(9201):376-7.
D. Haegert;M.D. (Br.Col.), F.R.C.P.(C)
Email: david.haegert [at] muhc.mcgill.ca (Dr. David Haegert)
Dr. David G. Haegert earned his undergraduate degree from the University of Victoria, British Columbia, Canada, and his medical degree from the University of British Columbia. He completed his internship at the Royal Victoria Hospital, Montreal, and his residency training in Anatomic Pathology in the McGill University teaching hospitals. He received post-doctoral training in Immunology at the University of Cambridge, Cambridge, England. Dr. Haegert is a Fellow of the Royal College of Physicians and Surgeons of Canada in Anatomic Pathology.
Dr. Haegert conducts research focusing on multiple sclerosis and possible biomarkers that predict rates of disease progression in multiple sclerosis and responses to therapy.
Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.
Zastepa E, Fitz-Gerald L, Hallett M, Antel J, Bar-Or A, Baranzini S, Lapierre Y, Haegert DG.
Neurology. 2014 Feb 25;82(8):681-90
Castleman's Disease: a rare finding in a pediatric neck.
Zawawi F, Varshney R, Haegert DG, Daniel SJ.
Int J Pediatr Otorhinolaryngol. 2014 Feb;78(2):370-2
Diminished Th17(not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation
Darlington PJ et al (Canadian MS/BMT study group including Haegert DG)
Premature thymic involution and multiple sclerosis
J Neurol Neurophysiol 5:207, 2014
Multiple sclerosis: a disorder of altered T-cell homeostasis.
Mult Scler Int. 2011;2011:461304.
Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS).
Haegert DG, Hackenbroch JD, Duszczyszyn D, Fitz-Gerald L, Zastepa E, Mason H, Lapierre Y, Antel J, Bar-Or A.
J Neuroimmunol. 2011 Apr;233(1-2):233-9.
Obstacles to progress in MS: a personal story
J Mult Scler 1:e102, 2014
|934-1934 ex. 38777
I. Hüttner; M.D. (Budapest), Ph.D. (McGill) F.R.C.P. (C)
Professor Emeritus (Retired)
Email: eihuttner [at] hotmail.com (Dr. Istvan Hüttner)
Dr. Istvan Hüttner completed his MD degree with "Summa Cum Laude" at the Semmelweis Medical University, Budapest, Hungary in 1961. He started his career by teaching and pursuing research in vascular pathology in the 2nd Department of Pathology of the same University where he obtained his certificate in Anatomical Pathology and held the title of Assistant Professor. In 1967-68 he obtained a postdoctoral fellowship at the Faculte de Medicine de Paris, France, then in 1969-71 he was awarded a Canadian Arthritis and Rheumatism Society Fellowship at McGill University, Montreal, Canada. While holding this latter fellowship, he started his research that led to original discoveries on vascular endothelium and his prominence in the field of vascular cell biology. He obtained a post-doctoral PhD degree in 1973 at McGill University, certificates in Anatomical Pathology by the American Board of Pathology, the College des Medecins du Quebec and became Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) in 1975. He was appointed to Assistant Professor in 1973, Associate Professor in 1976 and promoted to Full Professor in 1981 at the Department of Pathology, McGill University. He spent a sabbatical year as Visiting Professor at the University of Geneva, Switzerland in 1983-84 where he was also recipient of the Zyma Award.
Until his retirement in 2000 Dr. Hüttner was also a Senior Pathologist at the Royal Victoria Hospital, Montreal. During the first two decades of his tenure at McGill University he excelled primarily in teaching and research and published over 120 scientific papers on the structure and function of vascular endothelium in normal and disease states, particularly cell junction morphology and assembly, including the first description of gap junctions in arterial endothelium, passage of protein tracers through arterial endothelium, cell to cell, and cell to matrix attachments, as well as on phenotypic modulation of vascular smooth muscle cells. He pursued additional research on the sarcolemmal membrane of hereditary and acquired, particularly catecholamine induced cardiac muscle cell alterations. In the last 10 years of his active McGill University/Royal Victoria Hospital position he shifted from a primary research oriented career toward service in diagnostic surgical pathology, an activity that he continued to practice part time for several years after his retirement at various McGill Hospitals, particularly in the Sir Mortimer B. Davies Jewish General Hospital and in the St. Mary's Hospital. As recognition of his many years of meritorious service as Full Professor, McGill University conferred him the honorific title of Professor Emeritus in 2009.
Gap junctions in arterial endothelium.
Hüttner I, Boutet M, More RH.
J Cell Biol. 1973 Apr;57(1):247-52. No abstract available.
Studies on protein passage through arterial endothelium. I. Structural correlates of permeability in rat arterial endothelium.
Hüttner I, Boutet M, More RH.
Lab Invest. 1973 Jun;28(6):672-7. No abstract available
Studies on protein passage through arterial endothelium. II. Regional differences in permeability to fine structural protein tracers in arterial endothelium of normotensive rat.
Hüttner I, Boutet M, More RH.
Lab Invest. 1973 Jun;28(6):678-85. No abstract available
Studies on protein passage through arterial endothelium. 3. Effect of blood pressure levels on the passage of fine structural protein tracers through rat arterial endothelium.
Hüttner I, Boutet M, Rona G, More RH.
Lab Invest. 1973 Nov;29(5):536-46. No abstract available
Permeability alteration of sarcolemmal membrane in catecholamine-induced cardiac muscle cell injury. In vivo studies with fine structural diffusion tracer horse radish peroxidase.
Boutet M, Hüttner I, Rona G.
Lab Invest. 1976 May;34(5):482-8.
Cytoplasmic filaments and gap junctions in epithelial cells and myofibroblasts during wound healing.
Gabbiani G, Chaponnier C, Hüttner I.
J Cell Biol. 1978 Mar;76(3):561-8.
Heterogeneity of cell junctions in rat aortic endothelium: a freeze-fracture study.
Hüttner I, Peters H.
J Ultrastruct Res. 1978 Sep;64(3):303-8. No abstract available
Opening of tight junctions in cerebral endothelium. I. Effect of hyperosmolar mannitol infused through the internal carotid artery.
Nagy Z, Pappius HM, Mathieson G, Hüttner I.
J Comp Neurol. 1979 Jun 1;185(3):569-78.
Opening of tight junctions in cerebral endothelium. II. Effect of pressure-pulse induced acute arterial hypertension.
Nagy Z, Mathieson G, Hüttner I.
J Comp Neurol. 1979 Jun 1;185(3):579-85
Hüttner , I. The sarcolemma. In: "Drug-Induced Heart Disease". Ed.:M.A. Birstow, pp. 3-37. Elsevier/North-Holland biomedical Press, Amsterdam, 1980
Volume, surface, and junctions of rat aortic endothelium during experimental hypertension: a morphometric and freeze fracture study.
Hüttner I, Costabella PM, De Chastonay C, Gabbiani G.
Lab Invest. 1982 May;46(5):489-504.
Vascular endothelium: recent advances and unanswered questions.
Hüttner I, Gabbiani G.
Lab Invest. 1982 Nov;47(5):409-11. No abstract available
Remodeling of the rat aortic endothelial layer during experimental hypertension. Changes in replication rate, cell density, and surface morphology.
De Chastonay C, Gabbiani G, Elemér G, Hüttner I.
Lab Invest. 1983 Jan;48(1):45-52
Hüttner , I., Gabbiani, G.: Vascular endothelium in hypertension. Chapter 31 in: "Hypertension: Physiopathology and Treatment". Eds.: J.Genest, 0. Kuchel, P. Hamet, M. Cantin, pp.473488. McGraw-Hill, New York, 1983
Numerical densities of intramembrane particles in the cardiac sarcolemma of normal and myopathic Syrian hamsters.
Berry B, Poulsen R, Yunge L, Bruneval P, Fitchett D, de Chastonay C, Gabbiani G, Hüttner I.
J Mol Cell Cardiol. 1983 Aug;15(8):503-13.
Charge-related alterations of the cerebral endothelium.
Nagy Z, Peters H, Hüttner I.
Lab Invest. 1983 Dec;49(6):662-71.
Fracture faces of cell junctions in cerebral endothelium during normal and hyperosmotic conditions.
Nagy Z, Peters H, Hüttner I.
Lab Invest. 1984 Mar;50(3):313-22.
Aortic endothelial cell during regeneration. Remodeling of cell junctions, stress fibers, and stress fiber-membrane attachment domains.
Hüttner I, Walker C, Gabbiani G.
Lab Invest. 1985 Sep;53(3):287-302.
Perturbation of the sarcolemmal membrane in isoproterenol-induced myocardial injury of the rat. Permeability and freeze-fracture studies in vivo and in vitro.
Yunge L, Bruneval P, Cokay MS, Berry B, Peters H, Poulsen R, Hüttner I.
Am J Pathol. 1989 Jan;134(1):171-85.
Hüttner , I., Kocher, O., Gabbiani, G.: Endothelial and smooth muscle cells. Chapter 1 in: "Diseases of the Arterial Wall". Eds. J-P. Camilleri, C.L. Berry, J.N. Flessinger, J. Bariety, pp. 3-41, Springer-Verlag, London, 1989.
Phenotypic features of smooth muscle cells during the evolution of experimental carotid artery intimal thickening. Biochemical and morphologic studies.
Kocher O, Gabbiani F, Gabbiani G, Reidy MA, Cokay MS, Peters H, Hüttner I.
Lab Invest. 1991 Oct;65(4):459-70.
R.P. Michel; B.Sc., M.D., C.M. (McG.), F.R.C.P.(C)
Email: rene.michel [at] mcgill.ca (Dr. Rene P. Michel)
Dr. Michel obtained his B.Sc. and M.D.,C.M. degrees at McGill University, did two years of residency in Surgery before entering Pathology and obtaining his F.R.C.P. (Path). His research training was with Dr. James C. Hogg in pulmonary pathophysiology.
He was director of Surgical Pathology from 1988 to 1994, and Chair of the department of Pathology, McGill University and Pathologist-in-chief, Royal Victoria hospital from 1994-1999. He has been the Director of the Pathology component of Undergraduate medical and dental teaching since 1993, and is also director of Hematopathology and of Transplantation pathology at the McGill University Health center (MUHC). He has special clinical diagnostic interest in Hematopathology, Transplantation Pathology, and Pulmonary and Hepatic Pathology.
Dr. Michel’s research interests have been in the pulmonary vascular diseases and pulmonary hypertension, pulmonary edema and pulmonary fibrosis, morphometry; clinical research interests are in Hematopathology and Transplantation pathology (hepatic, cardiac, pancreatic, renal).
Acute respiratory distress syndrome: 30 years later.
Lesur, O., Berthiaume, Y., Blaise, G., Damas, P., Deland, E., Guimond, J.-G., Michel, R.P.
Can. Respir. J. 6:71-86, 1999. (Review)
Pretransplantation recipient regulatory T cell suppressive function predicts delayed and slow graft function after kidney transplantation.
Nguyen MT, Fryml E, Sahakian SK, Liu S, Michel RP, Lipman ML, Mucsi I, Cantarovich M, Tchervenkov JI, Paraskevas S.
Transplantation. 2014 Oct 15;98(7):745-53
Hypertonic saline resuscitation of hemorrhagic shock diminishes neutrophil rolling and adherence to endothelium and reduces in vivo vascular leakage.
Pascual JL, Ferri LE, Seely AJ, Campisi G, Chaudhury P, Giannias B, Evans DC, Razek T, Michel RP, Christou NV.
Ann Surg. 2002 Nov;236(5):634-42
Alveolar liquid clearance and sodium channel expression are decreased in transplanted canine lungs.
Sugita M, Ferraro P, Dagenais A, Clermont ME, Barbry P, Michel RP, Berthiaume Y.
Am J Respir Crit Care Med. 2003 May 15;167(10):1440-50
Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis.
Brimo F, Michel RP, Khetani K, Auger M.
Cancer. 2007 Aug 25;111(4):224-33. Review.
Primary effusion lymphoma involving three body cavities.
Brimo F, Popradi G, Michel RP, Auger M.
Cytojournal. 2009 Oct 9;6:21
Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate.
Huwait H, Wang B, Shustik C, Michel RP.
Am J Dermatopathol. 2010 Feb;32(1):65-70
Induction of pulmonary angiogenesis by adenoviral-mediated gene transfer of vascular endothelial growth factor.
Lambert V, Michel R, Mazmanian GM, Dulmet EM, Capderou A, Hervé P, Planché C, Serraf A.
Ann Thorac Surg. 2004 Feb;77(2):458-63; discussion 463
Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
Zlobec, I; Vuong, T; Compton, C C; Lugli, A; Michel, R P; et al.
British Journal of Cancer98.2 (Jan 29, 2008): 450-456.
Immunosuppression with budesonide for liver transplant recipients with severe infections.
Bhat, M., Ghali, P., Wong, P., Marcus, V.,. Michel, R., Cantarovich, M., Metrakos, P., Deschenes, M.
Liver Transplantation 18:262-3, 2012
Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma.
Abu-Sanad, A., Warsi, A., Michel, R.P., Nahal, A., Popradi, G., Storring, J.M., Liberman, A.S., Alcindor T.
Curr Oncol, 19:e289-291, 2012.
Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y, Metrakos P, Antecka E, Burnier MN, Ponton A, Gallinger S, Brodt P.
Oncogene. 2011 Sep 1;30(35):3766-83.
Pulmonary edema. Chapter 19 in “Physiologic Basis of Respiratory Disease”
Michel, R.P., Goldberg, P.
Edited by Q. Hamid, J. Shannon and J. Martin. BC Decker, Hamilton, ON. 2005, pages 203-236.
|934-1934 ex. 38779
A. Spatz; MSc., M.D. (Paris)
Email: alan.spatz [at] mcgill.ca (Dr. Alan Spatz)
Dr. Alan Spatz is Director of the Pathology Department at the Jewish General Hospital, and Professor of Pathology and Oncology at McGill University and holds a Canada Research Chair in Molecular Pathology. Dr. Spatz presently directs the X chromosome and Cancer research lab at the Lady Davis Institute and leads an international research group on cutaneous melanoma. He has authored more than 180 original scientific papers, reports, review articles, and books.
Dr. Spatz is also the Director of the McGill-JGH Dubrovsky Molecular Pathology Centre located at the Jewish General Hospital, which opened at the end of 2013. This new cutting-edge facility is leading the way to personalized medicine by using molecular analysis to identify tumour biomarkers to advance the diagnosis and treatment of cancer.
Dr. Spatz's research is focused on the X chromosome and its role in cancer. His lab is focused on three programs: the regulation and role of FoxP3 gene and its variants, the function of PPP2R3B gene as a metastasis suppressor gene, and the X chromosome-mediated allele specific expression. FoxP3 has a dual role and is both a key player to regulate the immune micro-environment, and a strong transcription regulator. Dr. Spatz and his team investigate whether its variants have different roles and may have a negative dominant effect. PPP2R3B is one of these fascinating genes that escapes X chromosome inactivation, and is located on the X in females and in the Y in males. In 2004, Dr. Spatz proposed a non-Knudsonian model of X chromosome-based tumor suppressor gene inactivation that then became validated with several genes, including WTX, UPX, and now PPP2R3B.
Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.
Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A.
Hum Pathol. 2014 Oct;45(10):2006-13
From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting.
van Kempen LC, Spatz A.
Mol Oncol. 2014 Jun;8(4):781-2.
Eggermont AM, Spatz A, Robert C.
Lancet. 2014 Mar 1;383(9919):816-27.
Biopsies: next-generation biospecimens for tailoring therapy.
Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G.
Nat Rev Clin Oncol. 2013 Aug;10(8):437-50.
Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?
Eggermont AM, Spatz A, Lazar V, Robert C.
Curr Opin Oncol. 2012 Mar;24(2):137-40.
Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies.
Batist G, Wu JH, Spatz A, Miller WH Jr, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M.
Front Pharmacol. 2011 Oct 5;2:59.
Melanoma--the pieces of the puzzle finally start coming together! Preface.
Spatz A, Eggermont AM.
Mol Oncol. 2011 Apr;5(2):113-5.
The dual role of the X-linked FoxP3 gene in human cancers.
Redpath M, Xu B, van Kempen LC, Spatz A.
Mol Oncol. 2011 Apr;5(2):156-63.
C.M. Telleria, Ph.D. (University of San Luis Argentina)
Email: carlos.telleria [at] mcgill.ca (Carlos Telleria)
Dr. Carlos Telleria is a reproductive endocrinologist whose research focuses on understanding the molecular mechanisms driving the physio-pathology of reproductive-related tissues. Dr. Telleria received his doctoral training from the National Council for Scientific and Technical Research (Conicet) of Argentina, and acquired postdoctoral expertise at the Department of Physiology, College of Medicine of the University of Illinois at Chicago. Before joining the Department of Pathology at McGill University, Dr. Telleria navigated the academic ranks at the Division of Biomedical Sciences of the Sanford School of Medicine of the University of South Dakota. During his years as an academic researcher Dr. Telleria mentored several undergraduate and graduate students, and received various awards for research and teaching excellence. Dr. Telleria is currently member of the editorial board of various peer review scientific journals, including Hormones and Cancer, Scientific Reports, Biology of Reproduction, Reproductive Biology and Endocrinology, and Cancer Growth and Metastasis.
The primary research interest in Dr. Telleria’s laboratory is in the field of ovarian cancer biology and preclinical therapy. Ovarian cancer is a deadly disease mostly because is diagnosed when the tumor has already invaded the peritoneal cavity. Diagnosed patients undergo surgery and platinum-based chemotherapy. This standard of care is initially effective, leading to disease remission for about two years in the standard responder. Ultimately, however, the disease recurs and no longer responds to previous therapy. Therefore, novel therapies for ovarian cancer are desperately needed. The overall approach in Dr. Telleria’s lab to develop new potential treatments for this disease is to consider that the time between remission and recurrence can be exploited by using a chronic intervention to maintain residual ovarian cancer cells, which had escaped initial therapy, in a non-proliferative or dormant status, and/or prevent their awakening. Within this scope, current investigations are tailored to understand the pathobiology of ovarian cancer within the microenvironment of the peritoneal cavity, to study the molecular mechanisms driving dormancy of cancer cells that had survived chemotherapy, and to exploit protein homeostasis to develop therapies for non-dividing cancer cells.
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
Zhang L, Hapon MB, Goyeneche AA, Srinivasan R, Gamarra-Luques CD, Callegari EA, Drappeau DD, Terpstra EJ, Pan B, Knapp JR, Chien J, Wang XJ, Eyster KM, Telleria CM (2016)
Molecular Oncology; 10: 1099-1117. PMID: 27233943;
Ovarian Cancer Research in the Post Genomic Era: Challenges and Opportunities
Goyeneche AA, Telleria CM (2016)
In: Gynecologic Cancers: Basic Sciences, Clinical, and Therapeutic Perspectives.
Samir Farghaly (Ed.), ISBN: 978-953-51-2254-8;
Long-term primary culture of a clear cell ovarian carcinoma reveals an epithelial-mesenchymal cooperative interaction.
Goyeneche AA, Koch M, Bell MC, Telleria CM (2015)
Cancer Cell International 15:88. PMID: 26405433;
Antiprogestins in gynecological diseases.
Goyeneche AA, Telleria CM (2015)
Reproduction 149 (1):R15-33. PMID: 25252652
Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin- induced cytotoxicity.
Gamarra-Luques CD, Hapon MB, Goyeneche AA, Telleria CM (2014)
Journal of Ovarian Research 7:45. PMID: 24795781
Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells.
Sane S, Abdullah A, Boudreau DA, Autenried RK, Gupta BK, Wang X, Wang H, Schlenker EH, Zhang D, Telleria C, Huang L, Chauhan SC, Rezvani K (2014)
Cell Death and Disease 5: e1118. PMID: 24625977
Repopulation of ovarian cancer cells after chemotherapy.
Telleria CM (2013)
Cancer Growth & Metastasis 6:15-21. PMID: 23544004
Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
Brandhagen BN, Tieszen CR, Ulmer TM, Tracy MS, Goyeneche AA, Telleria CM (2013)
BMC Cancer 13:35. PMID: 23351358
Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells.
Wempe SL, Gamarra-Luques CD, Telleria CM (2013)
Cancer Growth & Metastasis 6:1-13. PMID: 23420486
Drug repurposing for cancer therapy (Editorial).
Telleria CM (2012)
J Cancer Science & Therapy 4.7. PMID: 22984635
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.
Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM (2012)
BMC Cancer 112 (1):200. PMID: 22642877
Antiprogestins in Ovarian Cancer, Ovarian Cancer - Clinical and Therapeutic Perspectives, Samir Farghaly (Ed.)
Telleria CM, Goyeneche AA (2012)
Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDBG-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Goyeneche AA, Seidel EE, Telleria CM (2012)
Investigational New Drugs 30: 967-980. PMID: 21424700
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM (2011)
BMC Cancer 11:207. PMID: 21619605
Name and email
J. Arseneau; M.D. (Laval), F.R.C.P.(C)
Email: jocelyne.arseneau [at] mcgill.ca (Dr. Jocelyne Arseneau)
|934-1934 ex. 38771
C. Bernard; M.D. (Sher.)
Email: chantal.bernard [at] muhc.mcgill.ca (Dr. Chantal Bernard)
F. Brimo; M.D. (Syria), F.R.C.P.(C)
Email: fadi.brimo [at] mcgill.ca (Dr. Fadi Brimo)
Dr. Fadi Brimo's is a Staff pathologist at the Montreal General Hospital who specializes in Genito-Urinary Pathology and Cytology.
Morphological, clinical, and basic science studies related to tumors of the Genitourinary tract. The clinical and morphological studies areobservational or outcome-based and address issues impacting diagnostic surgical Pathology, including classification of tumors, original descriptions of histopathologic entities and the development of prognostic biomarkers using tissue microarrays of prostate, bladder and kidney cancer. The basic science work involves collaborations as primary or co-investigator with other McGill clinical departments and research institutions using single nucleotide polymorphism (SNP)-arrays or Fluorescence in situ hybridization (FISH)-assays applied to prostatic and renal carcinoma in the intent of achieving better characterization of the disease at the morphological and prognostic levels.
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA).
W. Kassouf, A. Aprikian, P. Black, G. Kulkarni, J. Izawa, L. Eapen, A. Fairey, A. So, S. North, R. Rendon, S.S. Sridhar, T. Alam, F. Brimo, N. Blais, C. Booth, J. Chin, P. Chung, D. Drachenberg, Y. Fradet, M. Jewett, R.Moore, C. Morash, B. Shayegan, G. Gotto, N. Fleshner, F. Saad, D. R. Siemens.
Can Urol Assoc J. 2016 Feb; 10(1-2): E46-80.
Neoadjuvant Chemotherapy-Related Histological Changes in Radical Cystectomy: Assessment Accuracy and Prediction of Response.
H.Wang, S. Solanki, S. Traboulsi, W. Kassouf, F.Brimo.
Accepted in Human Pathology.
Fumarate Hydratase-deficient Renal Cell Carcinoma is Strongly Correlated with Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
K.Trpkov, O. Hes, A. Agaimy, M. Bonert, P. Martinek, C. Magi-Galluzzi, G. Kristiansen, C. Lüders, G. Nesi, E. Comperat, M. Sibony, D. M. Berney, R. Mehra, F. Brimo, A. Husain, N. Frizzell, K. Hills, F. Maclean, B. Srinivasan, A. J. Gill. Accepted in the Am J Surg Pathol.
The atypical urothelial cell category in the Paris System: Strengthening the Achilles' heel.
F. Brimo, M. Auger.
Cancer Cytopathol. 2015 Dec 21.
Changes in the expression profiles of claudins during gonocyte differentiation and in seminomas.
G. Manku, A. Hueso, F. Brimo, P. Chan, P. Gonzalez-Peramato, N. Jabado, T. Gayden, M. Bourgey, Y. Riazalhosseini M. Culty.
Andrology. 2016 Jan; 4(1):95-110.
Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.
L. Florianova, B. Xu, S. Traboulsi, H. Elmansi, S. Tanguay, A. Aprikian, W. Kassouf, F. Brimo.
World J Surg Oncol. 2015 Nov;13:317.
The Molecular Taxonomy of Primary Prostate Cancer.
F. Brimo as part of the Cancer Genome Atlas Research Network Collaboration.
Cell. 2015 Nov 5;163(4):1011-25.
Genitourinary tuberculosis in North America: A rare clinical entity.
MW. Sourial, F. Brimo, R. Horn, S. Andonian.
Can Urol Assoc J. 2015 Jul-Aug;9(7-8)
Cystic clear cell papillary renal cell carcinoma: is it related to multilocular clear cell cystic neoplasm of low malignant potential?
F. Brimo, C. Atallah, G. Li, JR.Srigley.
Histopathology. (Available online, 2015 Aug 7).
Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant.
F. Brimo, S. Dauphin-Pierre, A. Aprikian, W. Kassouf, S. Tanguay, O. Ajise, C. Dongo, LR. Bégin.
Hum Pathol. 2015 Oct;46(10):1506-13.
BCG-related renal granulomas managed conservatively: A case series.
T. Al-Qaoud, F. Brimo, AG. Aprikian, S. Andonian.
Can Urol Assoc J. 2015 Mar-Apr;9(3-4).
Urine cytology: does the number of atypical urothelial cells matter? A qualitative and quantitative study of 112 cases.
F. Brimo, B. Xu, W. Kassouf, B. Khaliji, M. Charbonneau, A. Nahal, Y. Kanber, D. Caglar, M. Auger.
Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.
GA Barayan, AG Aprikian, J. Hanley, W. Kassouf, F. Brimo, LR Bégin, S. Tanguay.
World J Urol. 2015 Sep;33(9):1275-80.
First case of invasive squamous cell carcinoma in a stoma of a Monti ileovesicostomy.
Reid S, Althunayan A, Capolicchio JP, Brimo F, Kassouf W.
Can Urol Assoc J. 2014 Sep;8(9-10):E654-6.
Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.
Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A.
Hum Pathol. 2014 Oct;45(10):2006-13.
Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W.
Urol Oncol. 2014 Jul 15. pii: S1078-1439(14)00214-2
The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features.
Chevarie-Davis M, Riazalhosseini Y, Arseneault M, Aprikian A, Kassouf W, Tanguay S, Latour M, Brimo F.
Am J Surg Pathol. 2014 Jul;38(7):887-94.
The value of the "suspicious for urothelial carcinoma" cytology category: a correlative study of 4 years including 337 patients.
Ton Nu TN, Kassouf W, Ahmadi-Kaliji B, Charbonneau M, Auger M, Brimo F.
Cancer Cytopathol. 2014 Nov;122(11):796-803.
Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA, Brimo F, Bégin LR, Hanley JA, Liu Z, Kassouf W, Aprikian AG, Tanguay S.
BJU Int. 2014 Dec;114(6b):E99-E104.
The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, Tanguay S, Kassouf W, Aprikian A, Brimo F.
Hum Pathol. 2014 Mar;45(3):488-97
The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W, Brimo F.
Ann Diagn Pathol. 2014 Feb;18(1):27-32.
Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank.
Brimo F, Aprikian A, Latour M, Têtu B, Doueik A, Scarlata E, Hamel L, McKercher G, Saad F, Lacombe L, Carmel M, Chevalier S.
Biopreserv Biobank. 2013 Oct;11(5):285-90.
Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers.
Chan SW, Nguyen PN,
Cancer Med. 2013 Feb;2(1):63-75.
Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B, Abourbih S, Sircar K, Kassouf W, Mansure JJ, Aprikian A, Tanguay S, Brimo F.
Arch Pathol Lab Med. 2013 Oct;137(10):1326-36.
J. Epstein, F. Brimo. “Other Tumors of the Prostate Gland and Tumors of the Seminal Vesicle”, Surgical Pathology of the Genitourinary Tract. Lippincott Williams & Wilkins; Wolters Kluwer Health, First Edition, 2014. Pages 674-709.
S. Camilleri-Broët; M.D. Ph.D. (Paris)
Email: sophie.camilleri-broet [at] muhc.mcgill.ca (Dr. Sophie Camilleri-Broët)
Dr. Sophie Camilleri-Broët received her MD degree with a specialization in Pathology and her PhD from the medical and scientific University Pierre et Marie Curie (Paris). She then completed a one year research fellowship at the Fred Hutchinson Cancer Research Center (Seattle), and spent three months at the Genome Institute of Singapore as invited scientist. Dr. Camilleri-Broëtwent went on to practice Thoracic Pathology at Hôtel Dieu Hospital in Paris, and GI Pathology at the Hôpital Européen Georges Pompidou.
Dr. Camilleri-Broët’s main clinical areas of expertise are thoracic and GI pathology. She is also interested in translational research and more specifically on genomics and cancer, and has contributed to more than 50 peer-reviewed publications in international journals.
Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS, Camilleri-Broët S, Tan EH, Alifano M, Lim WT, Bobbio A, Zhang S, Ng QS, Ang MK, Iyer NG, Takano A, Lim KH, Régnard JF, Tan P, Broët P.
Int J Cancer. 2014 Sep 1;135(5):1092-100.
Genomic profiles specific to patient ethnicity in lung adenocarcinoma.
Broët P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Régnard JF, Lim D, Koong HN, Agasthian T, Miller LD, Lim E, Camilleri-Broët S, Tan P.
Clin Cancer Res. 2011 Jun 1;17(11):3542-50
Genomic aberrations in lung adenocarcinoma in never smokers.
Job B, Bernheim A, Beau-Faller M, Camilleri-Broët S, Girard P, Hofman P, Mazières J, Toujani S, Lacroix L, Laffaire J, Dessen P, Fouret P; LG Investigators.
PLoS One. 2010 Dec 6;5(12):e15145.
Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M, Loi M, Camilleri-Broet S, Dupouy S, Régnard JF, Forgez P.
Biochimie. 2010 Feb;92(2):164-70.
Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis.
Broët P, Tan P, Alifano M, Camilleri-Broët S, Richardson S.
BMC Med Genomics. 2009 Jul 14;2:43
Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.
Broët P, Camilleri-Broët S, Zhang S, Alifano M, Bangarusamy D, Battistella M, Wu Y, Tuefferd M, Régnard JF, Lim E, Tan P, Miller LD.
Cancer Res. 2009 Feb 1;69(3):1055-62.
Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays.
Tuefferd M, De Bondt A, Van Den Wyngaert I, Talloen W, Verbeke T, Carvalho B, Clevert DA, Alifano M, Raghavan N, Amaratunga D, Göhlmann H, Broët P, Camilleri-Broët S.
Genes Chromosomes Cancer. 2008 Nov;47(11):957-64.
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.
Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broët S.
PLoS One. 2007 Nov 7;2(11):e1138.
Catamenial and noncatamenial, endometriosis-related or nonendometriosis-related pneumothorax referred for surgery.
Alifano M, Jablonski C, Kadiri H, Falcoz P, Gompel A, Camilleri-Broet S, Regnard JF.
Am J Respir Crit Care Med. 2007 Nov 15;176(10):1048-53.
TRAF4 overexpression is a common characteristic of human carcinomas.
Camilleri-Broët S, Cremer I, Marmey B, Comperat E, Viguié F, Audouin J, Rio MC, Fridman WH, Sautès-Fridman C, Régnier CH.
Oncogene. 2007 Jan 4;26(1):142-7.
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.
Camilleri-Broët S, Crinière E, Broët P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphaël M, Iraqi W, Sautès-Fridman C, Colombat P, Hoang-Xuan K, Martin A.
Blood. 2006 Jan 1;107(1):190-6.
Perioperative analysis of biopsies issued from mediastinoscopy.
Alifano M, Charpentier MC, Perrotin C, Molina TJ, Magdeleinat P, Audouin J, Regnard JF, Camilleri-Broët S.
Surg Endosc. 2005 Nov;19(11):1456-9.
Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin.
Compérat E, Zhang F, Perrotin C, Molina T, Magdeleinat P, Marmey B, Régnard JF, Audouin J, Camilleri-Broët S.
Mod Pathol. 2005 Oct;18(10):1371-6.
Peroperative frozen section analysis of TTF-1 antigen expression.
Camilleri-Broet S, Alifano M, Morcos M, Comperat E, Magdeleinat P, Marmey B, Molina TJ, Régnard JF, Audouin J.
J Clin Pathol. 2004 Jan;57(1):98-100.
FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
Camilleri-Broët S, Mounier N, Delmer A, Brière J, Casasnovas O, Cassard L, Gaulard P, Christian B, Coiffier B, Sautès-Fridman C.
Leukemia. 2004 Dec;18(12):2038-40.
Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group).
Elie C, Geay JF, Morcos M, Le Tourneau A, Girre V, Broët P, Marmey B, Chauvenet L, Audouin J, Pujade-Lauraine E, Camilleri-Broët S; GINECO Group.
Br J Cancer. 2004 Aug 2;91(3):470-5.
|934-1934 ex. 38774
B. Case; B.Sc., M.D.,C.M., M.Sc. (McG.) Dipl. Occ. Hyg., F.R.C.P.(C)
Email: bruce.case [at] mcgill.ca (Dr. Bruce Case)
Dr. Bruce Case is a pathologist and epidemiologist at McGill University in Montreal, Canada. Following his residency in pathology at McGill University he trained with Graham Gibbs and obtained the Diploma in Occupational Hygiene at McGill in 1980, and worked as a post‐doctoral fellow and instructor at the Mount Sinai School of Medicine, New York, from 1980‐83. For this work he was supported by a Fellowship in Occupational Health Research, Conseil de la Recherche en Santé du Québec . While at Mount Sinai Dr. Case performed some of the first studies on asbestos‐mediated free radical release, with the help of the Young Investigator’s Award of the American Lung Association. On his return to McGill he joined with Corbett and Alison McDonald and Patrick Sébastien in the Dust Disease Research Unit: the focus of this group was the epidemiological study of diseases related to mineral fibre exposure using lung‐retained fibre in exposure assessment. In 1986 he received the National Health Scholarship of NHRDP (Canada) for his work in the field.
In 1988 Dr. Case moved to the University of Pittsburgh, where he succeeded Dr. Philip Enterline as Director of the United States Environmental Protection Agency Center for Environmental Epidemiology. He returned to McGill in 1992 and continues research, teaching, and clinical work there in Pathology, Epidemiology, Occupational Health and the McGill School of Environment.
Dr. Case has participated in and given lectures to workshops, and provided peer reviews and advice for many national and international agencies and professional societies on the subject of the exposure assessment and health effects of mineral fibres, including NIOSH, the U.S. Environmental Protection Agency (EPA), and the Centers for Disease Control (CDC, through ATSDR). Dr. Case reviews publications for a wide variety of journals in general medicine, environmental and occupational medicine, industrial hygiene, and risk analysis, including The Lancet, The New England Journal of Medicine, Risk Analysis, Environmental Research, the Canadian Medical Association Journal, Cancer Epidemiology, and Biomarkers, and Prevention.
Dr. Case’s peer‐reviewed research on asbestos and other mineral fibre and particle exposures and related diseases has been funded by American and Canadian public agencies including the Quebec and American Lung Associations, Fonds de Recherche Santé Québec (FRSQ), Institut National de Santé Publique du Québec (INSPQ), American Thoracic Society (USA), the United States Environmental Protection Agency (EPA), MRC/ CIHR (Canada), the National Cancer Institute (of Canada) and the Department of Health and Welfare/Health Canada (Canada). He has published over 140 scientific papers, chapters and abstracts on the results. Dr. Case is also an occasional consultant to North American Regulatory and other Agencies, Workman’s Compensation boards in four Canadian provinces, and to attorneys representing plaintiffs and/or defendants in asbestos litigation.
Dr. Cases’s main areas of research include asbestos exposure and disease, integration of pathology and epidemiology, mineral fibres and their health effects, mesothelioma, lung cancer, case-control studies, death certification, occupational lung disease, and environmental exposure assessment.
Many of Dr. Case's publications are available on ResearchGate.
Overreliance on a single study: there is no real evidence that applying quality criteria to exposure in asbestos epidemiology affects the estimated risk.
Berman DW, Case BW.
Ann Occup Hyg. 2012 Oct;56(8):869-78
Pleural mesothelioma surveillance: validity of cases from a tumour registry.
Labrèche F, Case BW, Ostiguy G, Chalaoui J, Camus M, Siemiatycki J.
Can Respir J. 2012 Mar-Apr;19(2):103-7.
Asbestos” to Environmental and “Low-Dose” Exposure Levels and Health Effects, Particularly Malignant Mesothelioma
Case BW, Abraham JL, Meeker G, Pooley FD and Pinkerton
Journal of Toxicology and Environmental Health 2011, Part B, 14: 1, 3 — 39.
Risk of mesothelioma and occupational exposure to asbestos and man-made vitreous fibers: evidence from two case-control studies in Montreal, Canada.
Pintos J, Parent ME, Case BW, Rousseau MC, Siemiatycki J.
J Occup Environ Med. 2009 Oct;51(10):1177-84.
Heterogeneity of exposure and attribution of mesothelioma: Trends and strategies in two American counties.
Case BW and Abraham JL
J. Phys. 2009 Conf. Ser. 151
Asbestos, smoking, and lung cancer: interaction and attribution.
Occup Environ Med. 2006 Aug;63(8):507-8.
Occupational exposure to asbestos and man-made vitreous fibers, and risk of lung cancer: evidence from two case-control studies in Montreal, Canada.
Pintos J, Parent ME, Rousseau MC, Case BW, Siemiatycki J.
J Occup Environ Med. 2008 Nov;50(11):1273-81.
Correlation of cytotechnologists' parameters with their performance in rapid prescreening of papanicolaou smears.
Djemli A, Khetani K, Case BW, Auger M.
Cancer. 2006 Oct 25;108(5):306-10.
Mineralogical and exposure determinants of pulmonary fibrosis among Québec chrysotile miners and millers.
Nayebzadeh A, Case BW, Massé J, Dufresne A.
Int Arch Occup Environ Health. 2006 Mar;79(3):227-36.
Mesothelioma in Quebec chrysotile miners and millers: epidemiology and aetiology.
McDonald AD, Case BW, Churg A, Dufresne A, Gibbs GW, Sébastien P, McDonald JC.
\Ann Occup Hyg. 1997 Dec;41(6):707-19.
Asbestos, asbestosis, and lung cancer: observations in Quebec chrysotile workers.
Case BW, Dufresne A.
Environ Health Perspect. 1997 Sep;105 Suppl 5:1113-9.
M.F. Chen; M.B., B.S. (Monash), F.R.C.P.(C)
Email: moyfong.chen [at] mcgill.ca (Dr. Moy Fong Chen)
P. Fiset, MDCM, PhD, FRCPC (McG)
Email:pierre.o.fiset [at] mail.mcgill.ca ( Dr. Pierre Fiset)
Marie-Christine Guiot; B.Sc., M.D. (Bordeaux) Appointed-interim-chair (2021)
Email: marie.christine.guiot [at] mcgill.ca (Dr. Marie-Christine Guiot)
T. Haliotis, M.D. (Greece), Ph.D. (Queen's)
Email: tina.haliotis [at] mcgill.ca (Dr. Tina Haliotis)
Dr. Tina Haliotis is a hematopathologist with a PhD in immunology and experience in basic scientific research in the fields of molecular and cellular oncology.
Dr. Haliotis' current interests lie in the area of translational research in the field of hematological malignancies, particularly lymphomas, with a subspecialty interest in primary cutaneous T-cell lymphoma.
Gastrointestinal stromal tumor with autonomic nerve differentiation and coexistent mantle cell lymphoma involving the appendix.
Rahimi K, Gologan A, Haliotis T, Lamoureux E, Chetty R.
Int J Clin Exp Pathol. 2008 May 20;2(6):608-13.
Identification and characterization of a transcript for a novel Rac GTPase-activating protein in terminally differentiating 3T3-L1 adipocytes.
Wooltorton EJ, Haliotis T, Mueller CR.
DNA Cell Biol. 1999 Apr;18(4):265-73.
v-Ras and v-Raf block differentiation of transformable C3H10T1/2-derived preadipocytes at lower levels than required for neoplastic transformation.
Raptis L, Brownell HL, Lu Y, Preston T, Narsimhan RP, Anderson S, Schaefer E, Haliotis T.
Exp Cell Res. 1997 Aug 25;235(1):188-97.
Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40.
Raptis L, Brownell HL, Corbley MJ, Wood KW, Wang D, Haliotis T.
Cell Growth Differ. 1997 Aug;8(8):891-901.
Ras(leu61) blocks differentiation of transformable 3T3 L1 and C3H10T1/2-derived preadipocytes in a dose- and time-dependent manner.
Raptis L, Yang J, Brownell H, Lai J, Preston T, Corbley MJ, Narsimhan RP, Haliotis T.
Cell Growth Differ. 1997 Jan;8(1):11-21.
Y. Kanber; M.D. (Turkey)
Email: yonca.kanber [at] muhc.mcgill.ca (Dr. Yonca Kanber)
|934-1934 ex. 62610
J. Karamchandani; M.D. (Stanford)
Email: jason.karamchandani [at] mcgill.ca (Dr. Jason Karamchandani)
Dr. Jason Karamchandani graduated from Harvard College and attended medical school at Stanford University School of Medicine, where he remained for his residency training in anatomic pathology. He followed up with fellowship training in surgical pathology and neuropathology. Dr. Karamchandani went on to practice neuropathology at St. Michael’s Hospital in Toronto, where he served as the director of the immunopathology laboratory.
Dr. Karamchandani’s research is focused on tumors of the central nervous system and peripheral nerves with a focus on molecular pathology, bioinformatics, and the identification and characterization of diagnostic and prognostic biomarkers.
Emphysematous esophagitis associated with Sarcina organisms in a patient receiving anti-inflammatory therapy.
Carrigan S, Grin A, Al-Haddad S, Iakovlev V, Streutker C, Moore T, Karamchandani J.
Histopathology. 2014 Nov 19
Chordoid meningiomas: Incidence and clinicopathological features of a case series over 18 years.
Di Ieva A, Laiq S, Nejad R, Schmitz EM, Fathalla H, Karamchandani J, Munoz DG, Cusimano MD.
Neuropathology. 2014 Nov 6.
Chordoid meningiomas: Incidence and clinicopathological features of a case series over 18 years.
Di Ieva A, Laiq S, Nejad R, Schmitz EM, Fathalla H, Karamchandani J, Munoz DG, Cusimano MD.
Neuropathology. 2014 Nov 6.
Sox10 is Superior to S100 in the Diagnosis of Meningioma.
Ng J, Celebre A, Munoz DG, Keith JL, Karamchandani JR.
Appl Immunohistochem Mol Morphol. 2014 Sep 26.
IDH mutation in glioma: new insights and promises for the future.
Turkalp Z, Karamchandani J, Das S.
JAMA Neurol. 2014 Oct;71(10):1319-25.
Co-occurrence of a cerebral cavernous malformation and an orbital cavernous hemangioma in a patient with seizures and visual symptoms: Rare crossroads for vascular malformations.
Choudhri O, Feroze AH, Lad EM, Kim JW, Plowey ED, Karamchandani JR, Chang SD.
Surg Neurol Int. 2014 Jun 19;5(Suppl 4):S148-54.
Ectopic prolactin-producing pituitary adenoma in a benign ovarian cystic teratoma.
Al-Bazzaz S, Karamchandani J, Mocarski E, Horvath E, Rotondo F, Kovacs K.
Endocr Pathol. 2014 Sep;25(3):321-3
Mouse models of glioblastoma: lessons learned and questions to be answered.
Janbazian L, Karamchandani J, Das S.
J Neurooncol. 2014 May;118(1):1-8.
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.
Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, Sinyuk M, Ransohoff RM, Lathia JD, Karamchandani J, Kohrt HE, Zhang P, Powers JP, Jaen JC, Schall TJ, Merchant M, Recht L, Brown JM.
Br J Cancer. 2014 Mar 4;110(5):1179-88
Flexible omnidirectional carbon dioxide laser as an effective tool for resection of brainstem, supratentorial, and intramedullary cavernous malformations.
Choudhri O, Karamchandani J, Gooderham P, Steinberg GK.
Neurosurgery. 2014 Mar;10 Suppl 1:34-4; discussion 43-5.
V. Marcus, M.D., C.M.(McG), F.R.C.P.(C)
Email: victoria.marcus [at] muhc.mcgill.ca (Dr. Victoria Marcus)
V.-H. Nguyen; M.D. (Montr.), F.R.C.P.(C)
van-hung.nguyen [at] muhc.mcgill.ca (Email: Dr Van-Hung Nguyen)
M. Pelmus; M.D.
Email: mpelmus [at] jgh.mcgill.ca (Dr. Manuela Pelmus)
Dr. Pelmus has received her MD and PhD degrees from the “Carol Davila” University of Medicine and Pharmacy in Bucharest, Romania. She underwent residency training in Pathology at the same institution, followed by fellowships training in Bone Pathology and in Soft Tissue Tumors at Cochin Hospital (Paris, France) and Bergonié Institute (Bordeaux, France).
Since her residency graduation, Dr. Pelmus has been staff pathologist at University Hospital and „Carol Davila” University of Medicine and Pharmacy (Bucharest, Romania), Sherbrooke University Hospital (Canada) and Jewish General Hospital, Montreal (Canada) with active implication in university teaching programs, research and clinical activity.
Soft Tissue and Bone Pathology
Triple-negative breast cancers; markers in breast and ovarian neoplasia; endometrial cancers; pathology of the synovium.
M. Pusztaszeri; M.D.
Email: marc.pusztaszeri.ccomtl [at] ssss.gouv.qc.ca (Dr. Marc Pusztaszeri)
Dr. Marc Pusztaszeri obtained his MD degree from University of Lausanne, Switzerland, in 2001. He then completed a six years residency program in Pathology at CHUV, Lausanne, Switzerland, including one year in radio-oncology. Shortly after finishing his residency, he practiced for 18 months in a private laboratory (Unilabs) before returning in the academic environment at Geneva University Hospitals in 2010, where he developed his current specialization of head and neck pathology, thyroid pathology, and cytopathology. In 2012, he did a visiting fellowship at the Massachusetts General Hospital in Boston, where he established a strong connection with Prof. William Faquin, director of head and neck pathology. Since October 2017, Dr. Pusztaszeri has been an Associate Professor of Pathology at the McGill University as well as a staff pathologist at the Jewish General Hospital.
His clinical and research interests have focused mainly on cytopathology and surgical pathology of the thyroid gland and salivary gland tumors. He has authored or co-authored over 85 peer-reviewed publications, and has contributed to several chapters for important reference textbooks for thyroid and salivary gland cytopathology. He is recognized for his contributions for updating the Bethesda System for Reporting Thyroid Cytopathology, which plays a key role for the management of patients with thyroid nodules, and for the recent Milan System for Reporting Salivary Gland Cytopathology, an international team effort sponsored by the ASC and IAC which is expected to improve the management of patient with salivary gland lesions. He serves as an editorial board member for several important journals in the field of cytopathology and as an ad hoc peer-reviewer for many other journals.
Thyroidsalivary gland cytopathology and surgical pathology
have focused mainly on cytopathology and surgical pathology of the thyroid gland and salivary gland tumors
The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel
Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M, Chandra A, Cochand-Priollet B, Fadda G, Hirokawa M, Hong S, Kakudo K, Krane JF, Nayar R, Parangi S, Schmitt F, Faquin WC.
Acta Cytol. 2016;60(5):399-405. Epub 2016 Oct 21.
Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology.
Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, Gourmaud J, Vaickus LJ, Baloch ZW.
Cancer Cytopathol. 2016 Mar;124(3):181-7. doi: 10.1002/cncy.21631. Epub 2015 Oct 12.
Fine-needle aspiration of primary Langerhans cell histiocytosis of the thyroid gland, a potential mimic of papillary thyroid carcinoma.
Pusztaszeri MP, Sauder KJ, Cibas ES, Faquin WC.
Acta Cytol. 2013;57(4):406-12. doi: 10.1159/000348801. Epub 2013 Jul 10.
MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens.
Pusztaszeri MP, Sadow PM, Ushiku A, Bordignon P, McKee TA, Faquin WC.
Cancer Cytopathol. 2014 Apr;122(4):257-65. doi: 10.1002/cncy.21381. Epub 2013 Dec 2.
|340-8222 ext 4197
L. Rochon; M.D. (Sher.), F.R.C.P.(C)
Email: louise.rochon [at] mcgill.ca (Dr. Louise Rochon)
Dr. Louise Rochon is a Senior Pathologist at the Jewish General Hospital, with expertise in Head and Neck and Thyroid Pathology. At McGill, she is Associate Professor in Pathology and Otorhinolaryngology.
Ultrasound-guided fine-needle aspiration of thyroid nodules: does size matter?
Varshney R, Forest VI, Zawawi F, Rochon L, Hier MP, Mlynarek A, Tamilia M, Payne RJ.
Am J Otolaryngol. 2014 May-Jun;35(3):373-6.
Intraoperative parathyroid hormone level in parathyroidectomy: which patients benefit from it?
Zawawi F, Mlynarek AM, Cantor A, Varshney R, Black MJ, Hier MP, Rochon L, Payne RJ.
J Otolaryngol Head Neck Surg. 2013 Dec 19;42:56
Lymph node metastasis in thyroid papillary microcarcinoma: a study of 170 patients.
Varshney R, Pakdaman MN, Sands N, Hier MP, Rochon L, Black MJ, Payne RJ.
J Laryngol Otol. 2014 Oct;128(10):922-5.
Email: Dr.joshua.sonnen [at] mcgill.ca ( Joshua Aaron Sonnen)
Dr. Joshua Aaron Sonnen is a neuropathologist with an interest in the neuropathology of age-related, neurodegenerative disorders including Alzheimer's disease, Lewy body/Parkinson's disease, vascular brain injury, traumatic brain injury /chronic traumatic encephalopathy, motor neuron disease, and frontotemporal dementia. He has worked as co-leader of the neuropathology core of the Alzheimer's Disease Research Center at the University of Washington and with several population and community based studies of aging. He is interested in neuroepidemiology and genetics as well as the disease-modifying potential for drug and lifestyle exposures.
Biomarkers for Alzheimer's disease Sonnen JA, Keene CD, Montine KS, Li G, Peskind ER, Zhang J, Montine TJ. Expert Rev Neurother. 2007 Aug;7(8):1021-8. doi: 10.1586/14737220.127.116.111.
E.A. Zorychta; Ph.D. (McG.)
Email: edith.zorychta [at] mcgill.ca (Dr. E.Zorychta)
Name and email
O. E. Ajise, M.D., F.C.A.P., F.R.C.P.(C)
Email: oluyomi.ajise [at] muhc.mcgill.ca (Dr. Yomi Ajise)
Dr. Oluyomi (Yomi) Ajise is a Board certified in Anatomic Pathology in Canada by the Royal College of Physicians and Surgeons of Canada; and in Anatomic Pathology and Clinical Pathology in the United States by the American Board of Pathology. She is a fellow of the Royal College of Physicians and Surgeons of Canada and a fellow of the College of American Pathologists.
Prior to coming to McGill, Dr. Ajise completed two fellowships at the Memorial Sloan-Kettering Cancer Center in New York focusing on (i) Oncologic Surgical Pathology and (ii) Hematopathology; with the latter expected to be completed in June 2014. She received her MD degree from Howard University College of Medicine in Washington, DC in 2005 where she graduated with distinction and was honored as Medical School Valedictorian. She subsequently completed two years of residency in Internal Medicine at New-York-Presbyterian Hospital/Weill Cornell Medical Center; followed by four years of residency training in Anatomic and Clinical Pathology at New York University in New York, USA.
Dr. Ajise's professional areas of interest include optimum clinical diagnostic services; teaching and clinical research including collaborative research studies.
M. Alameldin; M.D., F.R.C.P.(C)
Email: malameldin [at] jgh.mcgill.ca (Dr. Mona Alameldin)
O. Aleynikova; M.D. (Dalhousie), F.R.C.P.(C)
Email: olga.aleynikova [at] mcgill.ca (Dr. Olga Aleynikova)
K. Bakdounes; M.D. (Syria)
Email: khldoon.bakdounes [at] ssss.gouv.qc.ca (Dr. Khldoun Bakdounes)
Dr. Khldoun Bakdounes is the Chief pathologist at St Mary Hospital center and Assistant Professor at the department of Pathology, McGill University. He received his MD in 1994 from the Damascus University Damascus, Syria. Dr. Bakdounes pursued his training as a pathologist at State University of New York, combining this with his Masters in Public Health. Thereafter, he finished two fellowships in selective pathology and cytopathology. He was board certified as an anatomical and clinical pathologist in 2006 and cytopathology in 2008. Dr. Bakdounes is a fellow of the Royal College of Physicians of Canada since 2007 and is a Licentiate of the Medical Council of Canada.
Dr. Bakdounes' main areas of interest are breast pathology, hematopathology and fine needle aspiration cytopathology.
M. Blumenkrantz; M.D. (McG)
Email: miriam.blumenkrantz [at] muhc.mcgill.ca (Dr. M. Blumenkrantz)
J. Burnier Ph. D. (McGill)
Julia.burnier [at] mcgill.ca (Email: Dr. Julia Burnier)
Dr. Burnier completed a PhD in molecular and cell biology at McGill University (Experimental Medicine). The focus of her PhD was the molecular mechanisms underlying invasion and metastasis. Dr. Burnier went on to pursue related post-doctoral training at McGill and at the Centre for Genomic Regulation (Barcelona, Spain). She then studied cancer genomics in clinical trials at the Princess Margaret Hospital (Toronto).
Her lab within the Cancer Research Program (CRP) of the RI-MUHC-RI aims to uncover the role and mechanisms of tumor-derived (circulating) molecules in tumor progression and metastasis, in order to develop novel accurate and sensitive biomarkers and identify new targeted therapeutic strategies. Using liquid biopsy samples and cell models, she investigates the role of circulating nucleic acids and tumour-derived extracellular vesicles (EVs) in mediating tumour metastasis via communication with and reprograming of the tumor microenvironment.
Understanding the dynamic molecular changes that occur during tumor progression and metastasis, with a focus on ocular tumors. Identifying tumor markers that can be used to track disease through liquid biopsies.
Expertise: cell biology, genomics, cancer biology, uveal melanoma, metastasis, ophthalmology.
Eyelid Mycetoma Masquerading as Sebaceous Carcinoma.
Zoroquiain P, Alghamdi S, Arthurs B, Levin L, Sheppard DC, Ralph B, Burnier J, Burnier MN. Ophthal Plast Reconstr Surg. 2017 May/Jun;33(3S Suppl 1):S101-S104. doi: 10.1097/IOP.0000000000000657.
Analysis of HSP90 Expression Is Valuable in the Differential Diagnosis of Ocular Surface Squamous Lesions
Zoroquiain P, Faingold D, Algahmdi S, Vila N, Logan P, Sanft DM, Toledo Dias AB, Aldrees S, Bravo-Filho V, Burnier J, Burnier MN. Ophthalmic Res. 2016 Jul;56(2):79-84. doi: 10.1159/000445212. Epub 2016 May 11./aqw007
Pericyte Status in Routinely Discarded Vitrectomy Samples May Be an Early Marker of Diabetic Retinopathy.
Zoroquiain P, Vila N, Bravo-Filho V, Dias AB, Sanft DM, Chen J, Galic J, Kapusta M, Mastromonaco C, Aldrees SS, Burnier J, Burnier MN Jr. Am J Clin Pathol. 2016 Mar;145(3):385-92. doi: 10.1093/ajcp/aqw007.
Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Burnier JV, Wang N, Michel RP, Hassanain M, Li S, Lu Y, Metrakos P, Antecka E, Burnier MN, Ponton A, Gallinger S, Brodt P Oncogene. 2011 Sep 1;30(35):3766-83. doi: 10.1038/onc.2011.89. Epub 2011 Apr 11.
D. Caglar; M.D. (Turkey)
Email: derin.caglar [at] muhc.mcgill.ca (Dr. Derin Caglar)
J. Chepovetsky; M.D. (USA)
Email: julie.chepovetsy.COMTL [at] ssss.gouv.qc.ca (Julie Chepovetsky)
A. Florea; M.D. (Romania)
Email: anca.florea [at] mcgill.ca (Dr. Anca Florea)
Dr.Anca Florea received her MD degree from the “Iuliu Hatieganu” University of Medicine and Pharmacy in Cluj-Napoca, Romania. She underwent residency training in Anatomic and Clinical Pathology at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, USA, followed by a one year fellowship training in Breast and Gynecologic Pathology at the same institution. Since July 2011, Dr. Florea has been an Assistant Professor of Pathology at the McGill University as well as staff pathologist at the Jewish General Hospital in Montreal, Canada.
Breast Pathology, Gynecologic Pathology, Thyroid Pathology
Dr. Florea's research interests includes the papillary lesions of the breast (especially the encapsulated papillary carcinoma and solid papillary carcinoma) and phyllodes tumors, as well as clear cell carcinoma of the ovary.
Dr Livia Florianova, MD, MSc, FRCPC
Email: livia.florianova [at] mail.mcgill.ca (Dr. Florianova)
Dr Livia Florianova, MD, MSc, FRCPC is thrilled to have joined the Department of Pathology at McGill University as an Assistant Professor at the Jewish General Hospital in July 2018. She completed her medical studies at Université Laval in Quebec City (2012), where she also obtained a Master's degree in Experimental Medicine (2011). Following her residency at McGill University (2012-2017), she trained one year at the University of Toronto as a Surgical Pathology fellow at St. Michael's Hospital with independent sign-out and staff responsibilities. During that year, she also completed electives at the Toronto General Hospital and the Sunnybrook Health Sciences Centre. Livia's main areas of interest are breast, head & neck and thyroid pathology. She aims to enrich her understanding of these topics though clinical research projects including collaborative research studies. She also looks forward to actively participate in resident education. In her spare time, Livia catches up on art history, music, plays hockey, swims and explores the beauties of the natural world.
L. Fu, M.D.,C.M. (McG)
Email: lili.fu [at] muhc.mcgill.ca (Dr. Lili Fu)
A. Gologan; M.D. (Romania)
Email: adrian.gologan [at] mcgill.ca (Dr. A. Gologan)
A. Gregorieff B.Sc. ( Université Laval), M.Sc. (McGill University), Ph.D. (Universiteit Utrecht)
Email: Dr.alex.gregorieff [at] mcgill.ca ( )alex.gregorieff [at] mcgill.ca (A Gregorieff)
My current research interests stem from my doctoral thesis in the lab of Dr. Hans Clevers in the Netherlands. During this time, I studied the Wnt/Tcf pathway and its role in driving intestinal development and homeostasis. Next, I moved to Toronto to pursue my postdoctoral training in the lab of Dr. Jeff Wrana at the Lunenfeld-Tanenbaum Research Institute. Here, I became interested in studying the role of the Hippo signaling effector, Yap, in intestinal stem cells during regeneration and cancer initiation. In 2017, I was appointed assistant professor in the department of pathology at McGill University. My future research goals will be to study the role of the Hippo pathway in stromal cells during gut homeostasis and tumorigenesis. Secondly, I am also interested in dissecting the signals underlying cellular plasticity of adult stem cells. To achieve these goals, I am currently developing a broad range of genetic tools including Cre-lox based mice for gene targeting and lineage tracing experiments, as well as ex vivo organoid culture systems.
Hippo signalling in intestinal regeneration and cancer
Gregorieff A, Wrana JL
Curr Opin Cell Biol 2017, 48:17-25.
A critical role for NF2 and the Hippo pathway in branching morphogenesis
Reginensi A, Enderle L, Gregorieff A, Johnson RL, Wrana JL, McNeill H
Nat Commun 2016, 7:12309.
YAP and TAZ control peripheral myelination and the expression of laminin receptors in Schwann cells
Poitelon Y, Lopez-Anido C, Catignas K, Berti C, Palmisano M, Williamson C, Ameroso D, Abiko K, Hwang Y, Gregorieff A, et al.
Nat Neurosci 2016, 19:879-887
Seeing is believing: Wnt3 localization in the gut epithelium
Gregorieff A, Wrana JL
Cell Res 2016, 26:515-516
Multiple roles for the hippo effector yap in gut regeneration and cancer initiation
Gregorieff A, Wrana JL
Mol Cell Oncol 2016, 3:e1143992
YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells
Dey A, Robitaille M, Remke M, Maier C, Malhotra A, Gregorieff A, Wrana JL, Taylor MD, Angers S, Kenney AM
Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer
Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL
Nature 2015, 526:715-718
S.Jung; M.D. (Korea)
Email: sung-mi.jung [at] muhc.mcgill.ca (Dr. Sungmi Jung)
J. Lavoie; M.D., Ph.D. (Laval)
Email: jlavoie [at] muihc.mcgill.ca (Dr. )jlavoie [at] muihc.mcgill.ca (Josée)jlavoie [at] muihc.mcgill.ca ( Lavoie)
VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.
Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, Ripeau JS, Killary AM, Davis EC, Lavoie J, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN.
Mol Oncol. 2013 Jun;7(3):513-30.
Canadian College of Medical Geneticists guidelines for the indications, analysis, and reporting of cancer specimens.
Dawson AJ, McGowan-Jordan J, Chernos J, Xu J, Lavoie J, Wang JC, Steinraths M, Shetty S.
Curr Oncol. 2011 Oct;18(5):e250-5.
CCMG guidelines: prenatal and postnatal diagnostic testing for uniparental disomy.
Dawson AJ, Chernos J, McGowan-Jordan J, Lavoie J, Shetty S, Steinraths M, Wang JC, Xu J; Canadian College of Medical Geneticists committees.
Clin Genet. 2011 Feb;79(2):118-24.
Blood transfusion risks and alternative strategies in pediatric patients.
Paediatr Anaesth. 2011 Jan;21(1):14-24.
Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia.
Rio Frio T, Lavoie J, Hamel N, Geyer FC, Kushner YB, Novak DJ, Wark L, Capelli C, Reis-Filho JS, Mai S, Pastinen T, Tischkowitz MD, Marcus VA, Foulkes WD.
N Engl J Med. 2010 Dec 30;363(27):2628-37.
Locus-specific dual color-probe for the enumeration of chromosome 18 in rapid FISH aneuploidy testing on uncultured amniocytes.
Soucy JF, Lavoie J, Duncan AM.
Prenat Diagn. 2010 Aug;30(8):811-2.
Epigenetic modification of the gene for the vitamin B(12) chaperone MMACHC can result in increased tumorigenicity and methionine dependence.
Loewy AD, Niles KM, Anastasio N, Watkins D, Lavoie J, Lerner-Ellis JP, Pastinen T, Trasler JM, Rosenblatt DS.
Mol Genet Metab. 2009 Apr;96(4):261-7.
Email: hilda-ruth.lopez-valle [at] ssss.gouv.qc.ca (Dr. Hilda Ruth Lopez-Valle)
A.T. Marcus; B.Sc., M.D., C.M. (McG), F.R.C.P.(C)
Email: alexander.marcus [at] ssss.gouv.qc.ca (Dr. Alexander T. Marcus)
Teddy Sutardji Nagaria,
Email: teddy.nagaria [at] mcgill.ca (Dr. Teddy Nagaria,)
Tuyet Nhung Ton Nu MD, FRCPC
Email: tuyet.tonnu [at] mcgill.ca (Dr. Ton Nu)
934-1934 Ext. 143786
A. Omeroglu, M.D. (Turkey)
Email: atilla.omeroglu [at] muhc.mcgill.ca (Dr. Atilla Omeroglu)
|934-1934 ex. 62266
G. Omeroglu-Altinel, M.D. (Turkey)
Email: gulbeyaz.omeroglu-altinel [at] muhc.mcgill.ca (Dr. Gulbeyaz Omeroglu-Altinel)
934-1934 ex. 62233
F. Razaghi, M.D. (Iran)
Email: farshid.razaghi.chsm [at] ssss.gouv.qc.ca (Dr. Farshid Razaghi)
Dr. Razaghi received his MD from the “Beheshti” University of Medical science in Tehran, Iran. He underwent residency training in Pathology at McGill University, followed by fellowship training in Cytology at Dartmouth-Hitchcock Medical Center in New Hampshire, USA.
Dr. Razaghi is a staff pathologist at St-Mary's Hospital and actively participates in the teaching of medical students and residents.
Cytology, Soft Tissue and Bone Pathology, Dermatopathology and Gastrointestinal pathology
|345 3511 ex. 3731
Email: margaret.redpath [at] mcgill.ca (Dr. Margaret Redpath )
Dr. Redpath is an assistant professor in the Department of Pathology at McGill University and a practicing dermatopathologist at the Jewish General Hospital. She completed both her Bachelor of Science in Physiology and her medical degree at McGill University. During her residency training in Anatomical Pathology, Dr. Redpath began her Master of Science through the Royal College’s Clinician Investigator Program. Her research involves examining the role of tumor suppressor genes on the X chromosome in melanoma to better understand the significantly increased incidence and mortality of melanoma in men compared to women. Dr. Redpath recently received her PhD in Pathology from McGill University and completed her fellowship training in dermatopathology at Toronto General Hospital.
J. St. Cyr; M.D.,C.M. (McG.), F.R.C.P.(C)
Email: julie.st-cyr [at] ssss.gouv.qc.ca (Dr. Julie St-Cyr)
H. Wang; M.D. (China)
Email: hangjunwang [at] jgh.mcgill.ca (Dr. Hangjun Wang)
Name and email
B. S. Abdulkarim; M.D., Ph.D., (Paris) F.R.C.P.(C)
Email: bassam.abdulkarim [at] mcgill.ca (Dr. Bassam Abdulkarim)
Dr. Bassam Abdulkarim is an Associate Professor in the Department of Oncology (Director, Division of Radiation Oncology, since April, 2011) and principle investigator at the Research Institute of the MUHC. Dr. Abdulkarim joined the Department of Pathology as an associate member in 2013.
Dr. Abdulkarim’s main research focus is on translational research in Lung cancer and Brain tumor. His is currently investigating the effect of different types of radiation fractionation including ablative dose of radiation in lung cancer and brain tumor.
Dr. Abdulkarim’s major interest is to develop prognostic and predictive biomarkers to radiation alone or in combination with new-targeted therapies. In addition, one of his research interests is focusing on the “comprehensive approach of lung cancer, radiation-induced fibrosis, and development of new therapeutics.
YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells.
Jung K, Wu F, Wang P, Ye X, Abdulkarim BS, Lai R.
BMC Cancer. 2014 May 9;14:328.
Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.
Jung K, Wang P, Gupta N, Gopal K, Wu F, Ye X, Alshareef A, Bigras G, McMullen TP, Abdulkarim BS, Lai R.
Breast Cancer Res. 2014 Nov 8;16(6):470.
A Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors: Late Toxicity and Quality of Life.
Boychak A, Bauman G, Fisher B, Abdulkarim B, Amanie J, Fulton D, Murtha A, Patel S, Urtasun R, Ghosh S, Roa WH.
Am J Clin Oncol. 2014 Jan 22.
Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M, Abdulkarim B.
PLoS One. 2013 Aug 26;8(8):e71987.
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.
Radiat Oncol. 2013 Feb 20;8:38.
O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.
Chahal M, Abdulkarim B, Xu Y, Guiot MC, Easaw JC, Stifani N, Sabri S.
Mol Cancer Ther. 2012 Nov;11(11):2440-50.
C.J. Baglole; Ph.D. (University of Calgary)
Email: carolyn.baglole [at] mcgill.ca (Dr. Carolyn Baglole)
Dr. Baglole received her BSc and MSc from the University of Prince Edward Island, and her PhD from the University of Calgary. She then did postdoctoral research and subsequently joined the academic staff at the University of Rochester, before returning to Canada where she is currently an Assistant Professor in the Department of Medicine and an Associate Member in the Department of Pathology at McGill.
Research Interests: The research in her laboratory is aimed at identifying novel intracellular and molecular pathways that control the pathogenesis of chronic lung diseases associated with environmental exposures, particularly cigarette smoke. Her main focus is understanding how cigarette smoke-induced inflammation and cell death (apoptosis) are regulated. Chronic and persistent inflammation and the death of lung cells are involved in the etiology of lung diseases such as chronic obstructive pulmonary disease (COPD), which is almost always caused by cigarette smoke (>90% of cases). There is no cure for individuals afflicted with COPD and there are no effective therapies that can reduce disease progression. This is due, in part, to a lack of novel intracellular targets for the development of pharmacological therapies.
In this regard, her lab was the first to publish that the mere presence of a cellular receptor called the aryl hydrocarbon receptor (AhR) attenuates lung inflammation caused by cigarette smoke. This was a novel finding, as the normal physiological function of this receptor, which is best known for its ability to respond to synthetic toxicants, had not previously been described. Beyond its regulation of inflammation in the lung caused by cigarette smoke, they also investigate the role of the AhR in attenuating apoptosis, a feature that is characteristic of lung tissue destruction in COPD. Using genetic, molecular and biochemical approaches, together with in vitro and in vivo models of smoke exposure, her research is focused on establishing that the AhR is a novel and important regulator of apoptosis and understanding in vivo, and the role of the AhR in preventing morphological features of emphysema in the lung.
The NF-κB Family Member RelB Attenuates Cigarette Smoke Extract-induced Apoptosis in Lung Fibroblasts via Transcriptional Regulation of the Aryl Hydrocarbon Receptor
Iu M, Zago M, Rico de Souza A, Bouttier M, White JH, Hamid Q, Eidelman DH and Baglole CJ.
Free Rad Biol Med. Accepted, 2017.
Inhaled Pollutants: The Molecular Scene behind Respiratory and Systemic Diseases Associated with Ultrafine Particulate Matter
Traboulsi H, Guerrina N, Iu M, Maysinger D, Ariya P, Baglole CJ
Int J Mol Sci. 2017 Jan 24;18(2). pii: E243. doi: 10.3390/ijms18020243. Review.
Aryl hydrocarbon receptor (AhR)-dependent regulation of pulmonary miRNA by chronic cigarette smoke exposure
Rogers S, de Souza AR, Zago M, Iu M, Guerrina N, Gomez A, Matthews J, Baglole CJ.
Sci Rep. 2017 Jan 12;7:40539. doi: 10.1038/srep40539
Monocyte-derived fibrocytes induce an inflammatory phenotype in airway smooth muscle cells.
Lin TY, Venkatesan N, Nishioka M, Kyoh S, Al-Alwan L, Baglole CJ, Eidelman DH, Ludwig MS, Hamid Q.
Clin Exp Allergy. 2014 Nov;44(11):1347-60
Alterations in the expression of the NF-κB family member RelB as a novel marker of cardiovascular outcomes during acute exacerbations of chronic obstructive pulmonary disease.
Labonté L, Coulombe P, Zago M, Bourbeau J, Baglole CJ.
PLoS One. 2014 Nov 19;9(11):e112965.
Aryl hydrocarbon receptor-dependent regulation of miR-196a expression controls lung fibroblast apoptosis but not proliferation.
Hecht E, Zago M, Sarill M, Rico de Souza A, Gomez A, Matthews J, Hamid Q, Eidelman DH, Baglole CJ.
Toxicol Appl Pharmacol. 2014 Nov 1;280(3):511-25
Aryl hydrocarbon receptor (AhR) attenuation of subchronic cigarette smoke-induced pulmonary neutrophilia is associated with retention of
nuclear RelB and suppression of intercellular adhesion molecule-1 (ICAM-1).
de Souza AR, Zago M, Eidelman DH, Hamid Q, Baglole CJ.
Toxicol Sci. 2014 Jul;140(1):204-23
The NF-κB family member RelB regulates microRNA miR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts.
Zago M, Rico de Souza A, Hecht E, Rousseau S, Hamid Q, Eidelman DH, Baglole CJ.
Toxicol Lett. 2014 Apr 21;226(2):107-16
Genetic deletion of IL-17A reduces cigarette smoke-induced inflammation and alveolar type II cell apoptosis.
Chang Y, Al-Alwan L, Audusseau S, Chouiali F, Carlevaro-Fita J, Iwakura Y, Baglole CJ, Eidelman DH, Hamid Q.
Am J Physiol Lung Cell Mol Physiol. 2014 Jan;306(2):L132-43.
Aryl hydrocarbon receptor-dependent retention of nuclear HuR suppresses cigarette smoke-induced cyclooxygenase-2 expression independent of DNA-binding.
Zago M, Sheridan JA, Nair P, Rico de Souza A, Gallouzi IE, Rousseau S, Di Marco S, Hamid Q, Eidelman DH, Baglole CJ.
PLoS One. 2013 Sep 27;8(9):e74953.
Differential roles of CXCL2 and CXCL3 and their receptors in regulating normal and asthmatic airway smooth muscle cell migration.
Al-Alwan LA, Chang Y, Mogas A, Halayko AJ, Baglole CJ, Martin JG, Rousseau S, Eidelman DH, Hamid Q.
J Immunol. 2013 Sep 1;191(5):2731-41.
IL-8 production in response to cigarette smoke is decreased in epithelial cells from COPD patients.
Nadigel J, Audusseau S, Baglole CJ, Eidelman DH, Hamid Q.
Pulm Pharmacol Ther. 2013 Oct;26(5):596-602.
N. Braverman; MD, M.Sc. (Tulane University； Sarah Lawrence College )
Email: nancy.braverman [at] mcgill.ca (Dr。 Nancy Braverman)
Dr. Braverman received her BSc from Cornell University and her Master in Human Genetics from Sarah Lawrence College。 She then received her M.D. from Tulane University, completed residency training in Pediatrics at Yale-New Haven hospital, followed by a Fellowship in Clinical and Biochemical Genetics at Johns Hopkins. She then joined McKusick-Nathan's Institute of Genetic Medicine as an Assistant Professor at Johns Hopkins University, and subsequently joined McGill where she is now an Associate Professor with tenure in the Department of Medicine and an Associate Member in the Department of Pathology at McGill.
Research Interests: The research in her laboratory is focused on a group of inherited disorders caused by defects in the genes responsible for the proper function of peroxisomes, important components of cells that help to metabolize lipids, or fatty acids. Peroxisomal disorders can involve either the assembly of the peroxisome itself (as in peroxisome biogenesis disorders), or specific enzymes located in the peroxisome. All of these conditions feature the loss of enzymes required by the body to metabolize important lipids. The consequences are a progressive disease of the nervous system, eye, hearing, bone, liver, kidney and adrenal glands. Her laboratory engineers mouse models of the disorders to investigate how these enzyme defects cause disease. To provide patients and their families with better prognostic information and care, the laboratory has established a patient registry documenting variations in disease outcome and is identifying drugs and therapies that can improve outcomes. The clinical trial of one drug is underway.
Click on to see Dr. Braveman's current publications list
Sonia Cellot , M.D. , Ph.D. (Université de Montréal)
e-mail: sonia.cellot [at] umontreal.ca (Dr. Sonia Cellot )
Dr. Sonia Cellot is an Assistant Professor in the Department of Pediatrics at Université de Montréal and an investigator in the Viral and Immune Disorders and Cancers axis at CHU Sainte-Justine Research Center. She is a clinician-scientist with a BSc in Biochemistry from McGill, an MD from the Université de Montréal, Royal College certification in both Pediatrics and Hematology, and a PhD in Molecular Biology from the Université de Montréal. She has been a pediatric hematologist in the Hematology-Oncology Division of CHU Sainte-Justine since 2009, where she is responsible for the pediatric acute myeloid leukemia (AML) program and is the Assistant Director of the Immune disorders and Cancer research axis at CHU- Sainte-Justine . Clinical duties encompass direct patient care, mainly in the hematopoietic stem cell (HSC) transplantation unit, and diagnostic test development as medical advisor in the molecular biology laboratory. Since 2010, she has been the co-investigator of the pediatric branch of the Quebec Leukemia Cell Bank, in collaboration with Dr Josée Hébert, hematologist at Hôpital Maisonneuve-Rosemont, with the mandate to collect highly annotated pediatric AML and infant leukemia samples to support and promote research projects.
Her research focus is on hematopoietic stem cell (HSC) biology and the development of human synthetic leukemia models to identify therapeutic vulnerabilities in high fatality pediatric leukemia. Long-lived HSC sustain the constant production of all mature cell lineages in the blood system, and constitute the critical cellular component of transplantation procedures performed in oncology for high risk malignancies, including leukemia. Nonetheless, factors that dictate HSC fate remain poorly defined, and their isolation and ex vivo culture remain challenging, limiting their clinical applications. The main focus of the laboratory is to study the role of chromatin methylation in human HSC biology. Accessibility of the transcriptional machinery to the genetic code is mediated through the concerted actions of chromatin modifying enzymes. The Mll (Mixed Lineage Leukemia) gene, encoding for a histone methyltransferase (of lysine 4 on histone 3, or H3K4) is involved in normal HSC maintenance and mutated in >70% of infant leukemia cases. Once thought to be irreversible, histone methylation is now regarded as a highly dynamic process, since the identification of the histone demethylase LSD1 (KDM1A) in 2004. Previous work identified that JARID1B (KDM5B), an eraser of the H3K4 epigenetic mark, regulates the expression of stemness associated genes, and its knockdown leads to HSC expansion in culture. The implication of histone demethylases (HDM) in HSC biology and cancer development is being unraveled, and under active pharmacological investigation.
Click on to see Dr. Cellot's current publications list
P.J. Chauvin; M.Sc. (W.Ont.), D.D.S. (McG.)
Email: peter.chauvin [at] muhc.mcgill.ca (Dr. Peter J. Chauvin)
M. Divangahi; Ph.D. (McG)
Email: maziar.divangahi [at] mcgill.ca (Dr. Maziar Divangahi)
Dr. Maziar Divangahi completed his PhD in the Department of Medicine at McGill University in 2005. He went to pursue three fellowships in Molecular Immunology and Infectious Diseases at McMaster University, McGill and Harvard University before being appointed at McGill as an Assistant Professor in the departments of Medicine and Microbiology & Immunology. He joined the Department of Pathology as an associate member in 2012.
Dr. Divangahi's research focuses on investigating the cellular and molecular mechanisms involved in cross-talk between innate and adaptive immunity to major pulmonary infectious diseases such as influenza and tuberculosis. He believes that understanding the different arms of immunity are essential for the future development of an effective therapy or vaccine.
Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection.
Tzelepis F, Verway M, Daoud J, Gillard J, Hassani-Ardakani K, Dunn J, Downey J, Gentile ME, Jaworska J, Sanchez AM, Nédélec Y, Vali H, Tabrizian M, Kristof AS, King IL, Barreiro LB, Divangahi M.
J Clin Invest. 2014 Dec 22. pii: 77014.
Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy.
Giordano C, Mojumdar K, Liang F, Lemaire C, Li T, Richardson J, Divangahi M, Qureshi S, Petrof BJ.
Hum Mol Genet. 2014 Dec 30. pii: ddu735.
Freund's adjuvant, NOD2 and mycobacteria.
Behr MA, Divangahi M.
Curr Opin Microbiol. 2014 Dec 5;23C:126-132.
Targeting eicosanoid pathways in the development of novel anti-influenza drugs.
Coulombe F, Divangahi M.
Expert Rev Anti Infect Ther. 2014 Nov;12(11):1337-43.
NLRX1 prevents mitochondrial induced apoptosis and enhances macrophage antiviral immunity by interacting with influenza virus PB1-F2 protein.
Jaworska J, Coulombe F, Downey J, Tzelepis F, Shalaby K, Tattoli I, Berube J, Rousseau S, Martin JG, Girardin SE, McCullers JA, Divangahi M.
Proc Natl Acad Sci U S A. 2014 May 20;111(20):E2110-9.
Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages.
Coulombe F, Jaworska J, Verway M, Tzelepis F, Massoud A, Gillard J, Wong G, Kobinger G, Xing Z, Couture C, Joubert P, Fritz JH, Powell WS, Divangahi M.
Immunity. 2014 Apr 17;40(4):554-68
N-glycolylated peptidoglycan contributes to the immunogenicity but not pathogenicity of Mycobacterium tuberculosis.
Hansen JM, Golchin SA, Veyrier FJ, Domenech P, Boneca IG, Azad AK, Rajaram MV, Schlesinger LS, Divangahi M, Reed MB, Behr MA.
J Infect Dis. 2014 Apr 1;209(7):1045-54.
Nada Jabado, MD, PhD
nada.jabado [at] mcgill.ca (E-mail: Dr. Nada Jabado)
Dr. Nada Jabado is a Professor of Pediatrics and staff physician in the Department of Hematology and Oncology at the Montreal Children’s Hospital. She completed her residency in pediatrics with a specialization in hemato-oncology, obtained a PhD in Immunology in Paris and followed that by a postdoctoral fellowship in biochemistry at McGill. She began her career as an independent investigator at The Research Institute of the McGill University Health Centre in 2003, pioneering a research program in pediatric brain tumours which is now unparalleled. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumours. More importantly, they identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1) at amino acid positions K27 (Lysine to Methionine, K27M) and G34 (Glycine to Valine or Arginine, G34V/R). A true clinician-scientist, Dr. Jabado leads a lab comprised of 6 postdoctoral and clinical fellows, 6 graduate students and 5 research assistants/associates. Her ground-breaking work has created a paradigm shift in cancer with the identification of histone mutations in human disease for the first time. This finding has revolutionized the field, as the epigenome was a previously unsuspected hallmark of oncogenesis, thus linking development and what we now know are epigenetic-driven cancers. This work and other publications in the subject are considered landmark papers (over 3000 citations since 2012).
Dr. Jabado has over 150 peer-reviewed publications to her credit, with an impressive number of senior-author, high-impact publications in such prominent journals as Nature Genetics, Nature, Science and Cancer Cell, to name a few. She established the ICHANGE (International CHildhood Astrocytoma Novel Genomic and Epigenomic) Consortium which groups researchers from 17 countries. This is a unique set of resources which enables the scientific community to explore pediatric brain tumors in depth with the ultimate aim of offering better therapeutic options by providing datasets, international collaborations and access to technology to all members of participating countries.
Dr. Jabado is an international leader in the field of neuro-oncology and cancer, honored by invitations as Keynote and Guest Speaker at top ranked symposia and universities. She has received numerous national and international accolades while garnering prestigious awards throughout her career. She is one of the best-funded investigators at McGill, with grants from CIHR, FRSQ, Genome Canada, NIH, a Large Scale Genomic grant from Genome Canada as well as funding from philanthropic organizations. She was recently inducted as a Fellow to the Royal Society of Canada.
Dr. Jabado is part of a rare breed of physicians that can actively link research to the bedside, a true clinician scientist. Her dedication to scientific research in pediatric brain tumours and her passion for the patients in her care are inspiring and infectious to colleagues and trainees alike. Her coworkers describe her as The Tasmanian Devil, a moving force of nature that can uproot entire schools of thought with gale-force winds. Anyone who has witnessed her speak in public will also attest to this phenomenon. Legend has it that she lives on coffee and chocolates. Dr. Jabado considers downtime as time spent racing the ski slopes with her physician husband and three teenage children who are a family of avid skiers
As an independent Principal Investigator, Dr. Jabado's has embarked on elucidating genetic signatures of pediatric astrocytomas and examining how they compare to adults. These are deadly brain tumours that originate in brain and include glioblastomas (GBM, the highest grade of astrocytomas), which are one of the deadliest cancers in humans. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumors. They also identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1). These mutations lead to amino acid substitutions at key residues and are tightly correlated with a distinct global DNA methylation pattern, neuroanatomical locations and age specificities. Their findings position them as leaders in the field of HGA, at the forefront of significant breakthroughs for this deadly brain tumor. Crucial impediments to progress are the lack of reliable in vitro and in vivo models for these “oncohistones” and understanding their effects in driving tumors and therapeutic resistance. they aim to identify events affected downstream of each mutation, and validate targets in their new models to better advise the use of experimental or pipeline drug(s) or drug combinations that could be rapidly translated into clinical trials. Ultimately, based on their findings, patients could be stratified based on their genetic/molecular signature, and assigned to a beneficial therapeutic strategy, bringing needed effective interventions in this devastating cancer. Additionally, they established a TCGA-like initiative by creating the International CHildhood Astrocytoma INtegrated Genomic and Epigenomic (ICHANGE) Consortium. This is a unique set of resources which enables the scientific world to investigate astrocytomas in children. It includes databases and access to technology as well as international collaborations from 15 participating countries, including ~1500 annotated glioma tissue samples representative of all grades and ages.
Diffuse intrinsic pontine gliomas -current management and new biologic insights. Is there a glimmer of hope?
Cohen KJ, Jabado N, Grill J
Neuro Oncol. 2017 Mar 24. doi: 10.1093/neuonc/nox021.
Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature.
Fossey M, Li H, Afzal S, Carret AS, Eisenstat DD, Fleming A, Hukin J, Hawkins C, Jabado N, Johnston D, Brown T, Larouche V, Scheinemann K, Strother D, Wilson B, Zelcer S, Huang A, Bouffet E, Lafay-Cousin L
J Neurooncol. 2017 Mar;132(1):155-162. doi: 10.1007/s11060-016-2353-0.
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas
Papillon-Cavanagh S, Lu C, Gayden T, Mikael LG, Bechet D, Karamboulas C, Ailles L, Karamchandani J, Marchione DM, Garcia BA, Weinreb I, Goldstein D, Lewis PW, Dancu OM, Dhaliwal S, Stecho W, Howlett CJ, Mymryk JS, Barrett JW, Nichols AC, Allis CD, Majewski J, Jabado N.
Nat Genet. 2017 Feb;49(2):180-185. doi: 10.1038/ng.3757
Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.
Torchia J, ......, Jabado N, Huang A
Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.
Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma.
Fiset PO, Fontebasso AM, De Jay N, Gayden T, Nikbakht H, Majewski J, Jabado N, Albrecht S
Pediatr Blood Cancer. 2017 Feb;64(2):275-278. doi: 10.1002/pbc.26215
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, Murphy D, Venneti S, Hameed M, Pawel BR, Wunder JS, Dickson BC, Lundgren SM, Jani KS, De Jay N, Papillon-Cavanagh S, Andrulis IL, Sawyer SL, Grynspan D, Turcotte RE, Nadaf J, Fahiminiyah S, Muir TW, Majewski J, Thompson CB, Chi P, Garcia BA, Allis CD, Jabado N, Lewis PW.
Science. 2016 May 13;352(6287):844-9. doi: 10.1126/science.aac7272.
Jun-Li Liu, PhD. (McGill University)
Email: un-li.liu [at] mcgill.ca (Dr. J-L Liu)
Click on to see Dr. JL-Liu's current publications list
P. Metrakos; M.D. C.M. (McGill University)
Email: peter.metrakos [at] muhc.mcgill.ca (Dr. Peter Metrakos)
M. Park; Ph.D. (Glasgow University, Scotland)
Email: morag.park [at] mcgill.ca (Dr. Morag Park)
Dr. Morag Park is a James McGill Professor in the Departments of Biochemistry, Medicine and Oncology at McGill University, where she holds the Diane and Sal Guerrera Chair in Cancer Genetics. She is also the current Scientific Director of the CIHR Institute of Cancer Research. Dr. Park has published over 100 papers in peer-reviewed journals. Her work has been recognized with numerous awards including becoming a Fellow of the Royal Society of Canada.
Dr. Park has a long standing interest in the molecular mechanisms of cancer. More recently her interests include how changes in the tumor microenvironment modulate breast cancer progression. She founded the Breast Cancer Functional Genomics Group, which integrates breast cancer sample collection, laser capture microdissection microarray-based gene expression profiling and signature validation, and includes members from basic research, informatics as well as clinical surgery and pathology.
Deficiency of the chromatin regulator Brpf1 causes abnormal brain development.
You L, Zou J, Zhao H, Bertos NR, Park M, Wang E, Yang XJ.
J Biol Chem. 2015 Jan 7. pii: jbc.M114.635250.
Breast Cancer Anti-Estrogen Resistance-3 inhibits transforming growth factor-ß/Smad signaling and associates with favorable breast cancer disease outcomes.
Guo J, Canaff L, Rajadurai C, Fils-Aimé N, Tian J, Dai M, Korah J, Villatoro M, Park M, Ali S, Lebrun JJ.
Breast Cancer Res. 2014 Dec 13;16(6):476.
MS/MS-based strategies for proteomic profiling of invasive cell structures.
Havrylov S, Park M.
Proteomics. 2015 Jan;15(2-3):272-86.
Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.
Vadnais C, Shooshtarizadeh P, Rajadurai CV, Lesurf R, Hulea L, Davoudi S, Cadieux C, Hallett M, Park M, Nepveu A.
Biol Open. 2014 Sep 12;3(10):937-46.
p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition.
Hudson J, Ha JR, Sabourin V, Ahn R, La Selva R, Livingstone J, Podmore L, Knight J, Forrest L, Beauchemin N, Hallett M, Park M, Ursini-Siegel J.
Mol Cell Biol. 2014 Oct 1;34(19):3689-701.
Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, Page BD, Gunning PT, Ferri LE, Hallett M, Park M.
Sci Signal. 2014 Apr 22;7(322):ra38.
Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer.
Wallace JA, Li F, Balakrishnan S, Cantemir-Stone CZ, Pecot T, Martin C, Kladney RD, Sharma SM, Trimboli AJ, Fernandez SA, Yu L, Rosol TJ, Stromberg PC, Lesurf R, Hallett M, Park M, Leone G, Ostrowski MC.
PLoS One. 2013 Aug 16;8(8):e71533.
Sabah N.A. Hussain, M.D. Ph.D. Critical Care and Respiratory Divisions
Email: sabah.hussain [at] muhc.mcgill.ca (Dr. sabah Hussain)
Dr. Sabah Noori Abdul Hussain is a James McGill Professor in the Department of Medicine ,( Critical Care and Respiratory Divisions appointed since July 1st, 2005); Medical Director at Pulmonary Function Laboratories since july 1999 and the Research Director at Meakins-Christie Labs of the MUHC since july 1991. Dr. Hussain joined the Department of Pathology as an associate member in 2017.
Dr. Hussain is currently involved in three main areas of research. First, his laboratory is currently investigating molecular signaling pathways and mechanisms of action of angiogenesis factors in general and angiopoietins and Tie-2 receptors in particular. Current project include identification of transcription factor networks downstream from Tie-2 receptors both in endothelial cells and in cultured skeletal muscle satellite cells. In addition, his laboratory is exploring the biological functions of both angiopoietin-1 and angiopoietin-2 in regulating cytokine cascade and tissue injury in various models of inflammation including severe sepsis and acute lung injury. To achieve the objective in this area of research his laboratory has developed transgenic animal models to over-express angiopoietins selectively in the vasculature. His second area of research is the biological roles of angiopoietins in skeletal muscle regeneration with particular emphasis on ventilatory muscle function. In this regard, we are investigating the effectiveness of gene therapy in which angiopoietins are delivered in vivo in various models of skeletal muscle injury and regeneration including cardiotoxin necrosis model and mdx model of Duchenne Muscular Dystrophy. His third area of research interest is molecular mechanisms involved in skeletal muscle atrophy in general and regulation of autophagy and proteosomal pathways in particular. Current research project include assessing the contribution of autophagic pathway to skeletal muscle protein degradation in human diaphragm during mechanical ventilation.
Fibulin-5 Regulates Angiopoietin-1/Tie-2 Receptor Signaling in Endothelial Cells
Chan Wilson, Ismail Hodan, Mayaki Dominique, Sanchez Veronica, Tiedemann Kerstin, Davis Elaine C, Hussain Sabah N A,
PloS one, Volume 11, Issue 6, e0156994 (June 15, 2016)
Prolonged controlled mechanical ventilation in humans triggers myofibrillar contractile dysfunction and myofilament protein loss in the diaphragm
Hussain Sabah N A, Cornachione Anabelle S, Guichon Céline, Al Khunaizi Auday, Leite Felipe de Souza, Petrof Basil J, Mofarrahi Mahroo, Moroz Nikolay, de Varennes Benoit, Goldberg Peter, Rassier Dilson E,
Thorax, Volume 71, Issue 5, 436-45 (March 31, 2016)
Contribution of the Mitochondria to Locomotor Muscle Dysfunction in Patients With COPD
Taivassalo Tanja, Hussain Sabah N A,
Chest, Volume 149, Issue 5, 1302-12 (December 12, 2015)
Angiopoietin-1 inhibits toll-like receptor 4 signalling in cultured endothelial cells: role of miR-146b-5p
Echavarria Raquel, Mayaki Dominique, Neel Jean-Charles, Harel Sharon, Sanchez Veronica, Hussain Sabah N A, ,
Cardiovascular research, Volume 106, Issue 3, 465-77 (March 30, 2015)
Angiopoietin-1 enhances skeletal muscle regeneration in mice
Mofarrahi Mahroo, McClung Joseph M, Kontos Christopher D, Davis Elaine C, Tappuni Bassman, Moroz Nicolay, Pickett Amy E, Huck Laurent, Harel Sharon, Danialou Gawiyou, Hussain Sabah N A,
American journal of physiology. Regulatory, integrative and comparative physiology, Volume 308, Issue 7, R576-89 (January 21, 2015)
Reactive oxygen species regulation of autophagy in skeletal muscles
Rahman Mashrur, Mofarrahi Mahroo, Kristof Arnold S, Nkengfac Bernard, Harel Sharon, Hussain Sabah N A,
Antioxidants & redox signaling, Volume 20, Issue 3, 443-59 (2014)
Regulation of angiopoietin-1/Tie-2 receptor signaling in endothelial cells by dual-specificity phosphatases 1, 4, and 5,
Echavarria Raquel, Hussain Sabah N A,
Journal of the American Heart Association, Volume 2, Issue 6, e000571 (December 5, 2013)
Autophagic flux and oxidative capacity of skeletal muscles during acute starvation
Mofarrahi Mahroo, Guo Yeting, Haspel Jeffrey A, Choi Augustine M K, Davis Elaine C, Gouspillou Gilles, Hepple Russell T, Godin Richard, Burelle Yan, Hussain Sabah N A,
Autophagy, Volume 9, Issue 10, 1604-20 (August 15, 2013)
Angiogenesis-related factors in skeletal muscles of COPD patients: roles of angiopoietin-2
Mofarrahi Mahroo, Sigala Ioanna, Vassilokopoulos Theodoros, Harel Sharon, Guo Yeting, Debigare Richard, Maltais Francois, Hussain Sabah N A,
Journal of applied physiology (Bethesda, Md. : 1985), Volume 114, Issue 9, 1309-18 (January 10, 2013)
Muscle cell derived angiopoietin-1 contributes to both myogenesis and angiogenesis in the ischemic environment.
McClung Joseph M, Reinardy Jessica L, Mueller Sarah B, McCord Timothy J, Kontos Christopher D, Brown David A, Hussain Sabah N A, Schmidt Cameron A, Ryan Terence E, Green Tom D,
Frontiers in physiology, Volume 6, 161 (May 19, 2015)
Mechanisms of Chronic Muscle Wasting and Dysfunction after an Intensive Care Unit Stay. A Pilot Study
Dos Santos Claudia, Hussain Sabah N A, Mathur Sunita, Picard Martin, Herridge Margaret, Correa Judy, Bain Alexandra, Guo Yeting, Advani Andrew, Advani Suzanne L, Tomlinson George, Katzberg Hans, Streutker Catherine J, Cameron Jill I, Schols Annemie, Gosker H R, Batt J,
American journal of respiratory and critical care medicine, Volume 194, Issue 7, 821-830 (October 1, 2016.
Failed reinnervation in aging skeletal muscle
Aare Sudhakar, Spendiff Sally, Vuda Madhusudanarao, Elkrief Daren, Perez Anna, Wu Qinghua, Mayaki Dominique, Hussain Sabah N A, Hettwer Stefan, Hepple Russell T,
Skeletal muscle, Volume 6, Issue 1, 29 (September 1, 2016)
Wassim Kassouf, MD, CM, FRCSC
email: wassim.kassouf [at] muhc.mcgill.ca (Dr. Wassim Kassouf)
After medical school and residency at McGill University, Dr Wassim Kassouf completed a urologic oncology fellowship at M. D. Anderson Cancer Center in Houston, Texas. He then arrived on faculty in August 2006 at the McGill University Health Center, Montreal, Canada. He is a Professor in the Division of Urology and Vice-Chair, academic affairs, of the Department of Surgery at McGill University. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and renal cancer.
He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 270 peer-review manuscripts and book chapters. He is the founder of the national Canadian Bladder Cancer Network, a co-founder of Bladder Cancer Canada (BCC), co-chair of the National Cancer Institute of Canada’s disease-oriented group in bladder cancer, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. He has served as program director over the last 6 years and currently is a member of the Royal College Urology Examination board committee. Dr Kassouf is a graduate of the AUA Leadership Program and received several awards including the American Urological Association Young Urologist of the Year, AUA Research Scholar Award, Canadian Urological Association Scholarship Award, FRSQ Clinician Scientist Research Scholar Award, and the Everett C. Reid Teaching Excellence Award.
His clinical and translational research focuses on the biology and therapy of bladder cancer. His translational research over the recent years have been primarily on biomarkers and radiosensitization in bladder cancer.
Phase I clinical trial of everolimus combined with trimodality therapy in patients with invasive bladder cancer
Bachir B, Souhami L, Mansure JJ, Brimo F, Vanhuyse M, Sturgeon J, Cury F, Aprikian A, Tanguay S, and Kassouf W
(Bladder Cancer, in press)
Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer?
Monteiro LL, Kassouf W
Int Braz J Urol. 2017 Mar-Apr;43(2):184-187.
Quality indicators in the management of bladder cancer: A modified Delphi study.
Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W.
Urol Oncol. 2017 Jan 3. pii: S1078-1439(16)30410-0. doi: 10.1016/j.urolonc.2016.12.003
Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy
Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN, Kassouf W.
Eur Urol. 2017 Apr;71(4):545-557. doi: 10.1016/j.eururo.2016.09.035. Review.
The role of HMGB1 in radio-resistance of bladder cancer
Shrivastava S, Mansure JJ, Almajed W, Cury F, Ferbeyre G, Popovic M, Seuntjens J, Kassouf W
Mol Cancer Ther 15:471-9, 2016.
A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Mansure JJ, Nassim R, Chevalier S, Szymanski K, Rocha J, Aldousari S, Kassouf W
PLoS One. 8(2):e55997, 2013
Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment
Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf W
PLoS One. 2013 Jun 17;8(6):e65257.
Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A, Hicks J, Meeker A, Netto G, Kassouf W
Hum Pathol. 2013 Apr 23. doi:pii: S0046-8177(13)00078-6
Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.
Bell MD, Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W.
World J Urol. 2016 Oct;34(10):1405-9. doi: 10.1007/s00345-016-1795-5.
Does teaching of robotic partial nephrectomy affect renal function and perioperative outcomes?
Cerantola Y, Ploussard G, Kassouf W, Anidjar M, Bladou F.
Urol Oncol. 2017 Jan 6. pii: S1078-1439(16)30408-2. doi: 10.1016/j.urolonc.2016.12.001
Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Aziz A, Dobruch J, Hendricksen K, Kluth LA, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, Shariat SF, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.
World J Urol. 2017 Jan 10. doi: 10.1007/s00345-016-1995-z. [Epub ahead of print] Review.
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH.
J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017.
Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.
Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V.
J Urol. 2017 Mar;197(3 Pt 1):580-589. doi: 10.1016/j.juro.2016.09.078.
Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction.
Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF.
J Urol. 2017 Feb;197(2):287-295. doi: 10.1016/j.juro.2016.03.194. Review.
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).
Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN.
World J Urol. 2017 Mar;35(3):379-387. doi: 10.1007/s00345-016-1928-x.
Impact of Implementing the Paris System for Reporting Urine Cytology in the Performance of Urine Cytology: A Correlative Study of 124 Cases.
Hassan M, Solanki S, Kassouf W, Kanber Y, Caglar D, Auger M, Brimo F.
Am J Clin Pathol. 2016 Sep;146(3):384-90. doi: 10.1093/ajcp/aqw127.
Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank.
Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE.
Bladder Cancer. 2016 Apr 27;2(2):203-213.
Neoadjuvant chemotherapy-related histologic changes in radical cystectomy: assessment accuracy and prediction of response.
Wang HJ, Solanki S, Traboulsi S, Kassouf W, Brimo F.
Hum Pathol. 2016 Jul;53:35-40. doi: 10.1016/j.humpath.2016.02.011.
Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.
Eapen LJ, Jones E, Kassouf W, Lambert C, Morgan SC, Moussa M, Nam R, Parliament M, Russell L, Saad F, Siemens DR, Souhami L, Szumacher E, Tyldesley S, Xu Y, Zbieranowski I, Breau RH, Belanger E, Black P, Estey E, Bowan J, Bora B, Brundage M, Chung P, Fleshner N, Evans A, Bauman G, Izawa J, Davidson C, Brimo F.
Can Urol Assoc J. 2016 Mar-Apr;10(3-4):90-4. doi: 10.5489/cuaj.3456.
Goffredo Orazio Rinaldo Arena, MD, Chir. Vasc. (Ita), FRCS(C),
Email: goffredoarena [at] gmail.com (Dr. Goffredo Orazio Rinaldo Arena, MD)
Dr. Goffredo Arena graduated in Italy at the University of Catania in 1997. He then moved to England where he started his training in General and Vascular Surgery at the Royal Free Hospital in London. In 2003 he transferred to McMaster University in Hamilton to continue his training in General and Vascular Surgery. In 2006 he gained the Vascular Surgery fellowship Certificate in Italy and in 2007 he obtained his General Surgery Specialist Certificate in Canada and he became a fellow of the Royal College of Surgeons. In 2007 he relocated to Montreal and he completed back to back a fellowship in Minimally Invasive Surgery and a fellowship in HPB and multi-organ transplantation at McGill University.
His main research interest focus on horizontal transfer of malignant traits and he has become worldwide one of the main advocates of the genometastatic hypothesis. He has patented a novel blood test called MATERD for cancer screening and metastatic recurrence prediction. Recently he published on the reprogramming effect of human embryonic stem cells’ exosomes on cancer cells.
Transfer of malignant traits as opposed to migration of cells: A novel concept to explain metastatic disease.
Arena GO, Arena V, Arena M, Abdouh M.
Med Hypotheses. 2017 Mar;100:82-86. doi: 10.1016/j.mehy.2017.01.019
Reprogramming Malignant Cancer Cells toward a Benign Phenotype following Exposure to Human Embryonic Stem Cell Microenvironment.
Zhou S, Abdouh M, Arena V, Arena M, Arena GO.
PLoS One. 2017 Jan 9;12(1):e0169899. doi: 10.1371/journal.pone.0169899.
Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients.
Hamam D, Abdouh M, Gao ZH, Arena V, Arena M, Arena GO.
J Exp Clin Cancer Res. 2016 May 14;35:80. doi: 10.1186/s13046-016-0360-9
Kommerell's diverticulum and aneurismal right sided aortic arch: a case report and review of the literature.
Cinà CS, Arena OG, Clase CM, Bruin G.
Journal of Vascular Surgery 2000; 32: 1208-14
Ruptured mycotic thoracoabdominal aortic aneurysms: Three case reports and a systematic review.
Cinà CS, Arena OG, Fiture AO, Clase CM, Doobay B.
Journal of Vascular Surgery 2001; 33:861-7
Subclavian-carotido transposition to reconstruct the first portion of the subclavian artery: personal experience and review of the literature.
Cinà CS, Safar HA, Laganà A, Arena OG, Clase CM.
Journal of Vascular Surgery 2002; 35: 422-29
Cerebrospinal fluid drainage to prevent paraplegia during thoracic and thoracoabdominal aortic aneurysm surgery: A systematic review and a meta-analysis.
Hamam D, Abdouh M, Gao ZH, Arena V, Arena M, Arena GO.
Cina CS, Arena GO, et al.
Journal of Vascular Surgery 2004; 40: 36-44
The retrojugular approach to carotid endarterectomy- A safer technique?
Menon NJ, Krijgsmann B, Sciacca L, Arena GO, Hamilton G.
Journal of Vascular and Endovascular Surgery 2005; 29 (6):608-10
Laparoscopic versus open resection for colorectal cancer: a meta-analysis of oncologic outcomes.
Jackson TD, Kaplan GG, Arena G, Page JH, Rogers SO Jr
J Am Coll Surg 204:439–446 (2007)
Laparoscopic vs. open resection for colorectal cancer: A meta-analysis of oncologic outcomes
Jackson T.D., Kaplan G.G., Arena G., Page J.H., Rogers S.O.
Journal of Surgical Research February 2007 (Vol. 137, Issue 2, Page 248)
Staged hepatectomy for bilobar colorectal hepatic metastases
Jamal MH, Hassanain M, Chaudhury P, Tran TT, Wong S, Yousef Y, Jozaghi Y, Salman A, Jabbour S, Simoneau E, Al-Abbad S, Al-Jiffry M, Arena G, Kavan P, Metrakos P.
HPB (Oxford). 2012 Nov;14(11):782-9. doi: 10.1111/j.1477-2574.2012.00543.x. Epub 2012 Aug 26.
Dr. Joanna Przybyl Ph.D (KU Leuven)
Email: joanna.przybyl [at] mcgill.ca (Dr. Joanna Przybyl )
Dr. Joanna Przybyl received a joint Ph.D. degree in biomedical sciences from KU Leuven, Belgium and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. Her doctoral studies focused on identifying new prognostic and predictive markers for soft tissue sarcoma. She then joined the laboratory of Dr. Matt van de Rijn in the Department of Pathology at Stanford University, where she completed her postdoctoral training in computational biology. During her postdoctoral studies, Dr. Przybyl demonstrated potential clinical utility of ctDNA monitoring in patients with leiomyosarcoma and leiomyoma, discovered activation and prognostic role of hexosamine biosynthesis pathway in leiomyosarcoma, and identified macrophage infiltration in undifferentiated uterine sarcomas. In 2021, Dr. Przybyl joined the Department of Surgery of the McGill University as an Assistant Professor, and the Cancer Research Program of the Research Institute of the McGill University Health Centre (RI-MUHC) as a Junior Scientist. Dr. Przybyl is also an Associate Member in the Department of Pathology of the McGill University.
The research projects in the laboratory of Dr. Przybyl are focused on: 1) development of liquid biopsy (circulating tumor DNA) assays for patients with soft tissue tumors, 2) metabolic reprogramming in selected types of soft tissue tumors, and 3) multi-omic profiling of soft tissue tumors to identify new diagnostic markers and therapeutic targets in these tumors.